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ABSTRACT 
Systemic effects of periodontal disease have been a subject of interest for the past century, with intense focus converging 
since the past decade. Both rheumatoid arthritis (RA) and periodontal disease (PD) are immuno-inflammatory diseases 
with osteolysis as its hallmark feature. Activated T cells are known to modulate osteoclastogenesis. This thesis aimed to 
analyze the influence of PD on systemic inflammatory and immunological markers in both PD and RA subjects. 
Periodontal parameters, clinical (PI, BOP, PPD 3-<5mm and PPD ≥5mm) and radiographic (marginal bone loss or MBL) 
were investigated in four groups: RA with PD, RA without PD, PD and healthy groups. Immunosuppression of T cell 
activation via targeted surface protein was also studied. 
 
AIMS 
Study I aimed to investigate the expression and functional importance of low-density lipoprotein receptor-related 
protein1 (LRP1) in T cells.  
 
Study II aimed to investigate serum cytokines, chemokines, growth factors, enzymes and costimulatory proteins in 
association with periodontal conditions in PD and RA subjects. 
 
Study III aimed to investigate the serum markers osteopontin (OPN), tumor necrosis factor receptors 1 (TNFR1) and 2 
(TNFR2) receptor activator of nuclear factor‐kappa B ligand (RANKL) and RANKL/ osteoprotegerin (OPG) ratio and 
compare them in PD and RA groups. 
 
Study IV aimed to investigate the severity of both PD and RA and investigate a correlation between glycemia and 
periodontal disease parameters using ΣPPD Total and ΣPPD Disease index. 
 
RESULTS 
 
Study I showed that T cells shed LRP1, which probably explains the low LRP1 expression in T cells. Shedding 
of LRP1 antagonizes T cell adhesion to integrin ligands and TCR-induced activation.  Integrin ligands and 
CXCL12 antagonize shedding through a TSP-1-dependent pathway, whereas ligation of CD28 antagonizes 
shedding independent of TSP-1. The disappearance of LRP1 from the cell surface may provide basic 
immunosuppression at the T-cell level. 
 
Study II showed significant positive correlations for ST1A1, FGF-19 and NT-3 whereas EN-RAGE, DNER, CX3CL1 
and TWEAK associated inversely with BOP, PPD≥ 5mm and MBL but positively with number of teeth. CD markers 
(CD244, CD40, CDCP1, LIF-R, IL-10RA, CD5 and CD6) were found to be associated with BOP, shallow and deep 
pockets, MBL and number of teeth, either directly or inversely. CCL8, CX3CL1, CXCL10, CXCL11, CCL11, CCL4, 
CCL20, CXCL5, CXCL6, and CCL23 were positively associated with number of teeth. Other growth factors were 
directly associated with MBL (HGF) and number of teeth (VEGF-A, LAP TGFbeta-1). 
 
Study III showed OPN, TNFR1, TNFR2 and RANKL serum levels were the highest in the RA group with PD, while the 
RA group without PD were comparable to PD subjects only. 
The RANKL/OPG ratios were comparable between PD group and both RA groups with and without PD. Serum RANKL 
levels were associated with and PPD ≥ 5mm. 
 
Study IV showed that the indices correlated strongly with number of deep pockets. DAS28 score correlated positively 
with RF in RA subjects with and without PD. Serum levels of HbA1c were higher in PD, RA with PD and without PD 
subjects as compared to the healthy group.  HbA1c levels associated positively with PPD Total, PPD Disease, and MBL. 
Tooth adjusted PPD Total correlated with all periodontal parameters except for shallow pockets. 
 
CONCLUSIONS 
This thesis shows that periodontal disease is mirrored by a range of systemic immune markers, particularly those 
involved in inflammation. Furthermore, peripheral osteoclastogenesis is a feature of PD, comparable to RA. Overall, this 
thesis signifies the peripheral involvement of host immune system in combating PD essentially as an osteolytic disease 
and the need to approach PD measurement via a novel continuous index. The thesis also shows evidence that LRP1 
controls motility, adhesion and activation in T cells.  
Key words: periodontal disease, rheumatoid arthritis, inflammation, PPD, MBL, bone loss, cytokines, chemokines, T cell, RANKL, 
TNF receptors, index, HbA1c 
   
 
 
LIST OF SCIENTIFIC PAPERS 
 
 
 
 I.     J. Panezai, E. Bergdahl, K-G. Sundqvist. 
T-cell regulation through a basic suppressive mechanism targeting low-density lipoprotein 
receptor-related protein 1. 
Immunology. 2017;152: 308–327. 
 
 
II.      J. Panezai, A. Ghaffar , M. Altamash, K-G .Sundqvist, P-E. Engström, A. Larsson. 
Correlation of serum cytokines, chemokines, growth factors and enzymes with periodontal 
disease parameters. 
PLoS ONE 2017; 12(11): e0188945. 
 
 
III.     J. Panezai, A. Ghaffar, M. Altamash, P-E. Engström, A. Larsson. 
Periodontal Disease influences osteoclastogenic bone markers in subjects with and without 
rheumatoid arthritis. 
PLoS ONE 2018; 13(6):e0197235. 
 
 
IV.       J. Panezai, A. Ali, A. Ghaffar, D. Benchimol, M. Altamash, B. Klinge, A. Larsson,  
P-E. Engstrӧm. 
Probing Pocket Depth Total Index, Glycated Hemoglobin and Disease Severity 
Measurements in Subjects with and without Rheumatoid Arthritis. 
Submitted. 
  
   
CONTENTS  
 
INTRODUCTION    
                                                                                                                         
             Inflammation                  1 
 Acute inflammation                                                                                                               1 
 Chronic inflammation                                                                                                       2 
 Autoimmunity and autoinflammation                2 
Periodontal inflammation                                                                                                               3 
 Role of immune cells in periodontal disease                                                                        3 
 Neutrophils                                                                                                                            3 
 Macrophages                                                                                                                         3 
 T lymphocytes                                                                                                                       4 
 B lymphocytes                 5 
 Osteoclasts                                                                                                                             5 
 Cytokines, chemokines and growth factors               6 
 T lymphocyte regulation                                                                     8 
 
Epidemiology of periodontal disease                                                                                             9 
 Prevalence of PD                                                                                                                   9 
 Risk assessment for PD                                                                                                         9 
 
Periodontal Parameters                 11 
 Plaque/Oral biofilm                                                                                                               11 
 Bleeding on probing                                                                                                              11 
 Periodontal pocket depth                 11 
 Radiography                 11 
 
Rheumatoid Arthritis                                                                                                                      12 
Epidemiology                                                                                                                                    12 
 
Risk factors                  12 
 Genetics                  12 
 Epigenetics                 12 
 Smoking                                                                                                                                 12 
 Ethnicity and gender                                                                                                              12 
 Microbiota                  12 
  
 
 
Clinical diagnosis         13 
 Serology                                                                                                  13 
 Joint involvement        13 
 Systemic and extra articular manifestations                                           13 
 
Classification criteria        15 
 
 
AIMS OF THESIS                                                                                            16 
(1) GENERAL AIM         16 
 
(2) SPECIFIC AIMS         16 
1. Study I                                                                                                16 
2. Study II         16 
3. Study III         16 
4. Study IV                                                                                             16 
 
ETHICAL CONSIDERATIONS                                                                     16 
 
MATERIAL AND METHODS                                                                        17 
 Patients                                                                                            17 
 Healthy individuals         17 
 Cells          17 
 
Questionnaire          18 
Periodontal examination         18 
Radiographic evaluation         18 
DAS28          19 
Blood sample          19 
                      
 
                                                                                                               
 
Serological analyses         19 
 IgM RF and ESR         19 
 Anti-cyclic citrullinated peptide (anti-CCP) antibodies      19 
 HbA1C          20 
 Multiplex PEA-based immunoassay        20 
 ELISA          21 
 
 
 
Quantitative immunohistochemistry         21 
 
Small interfering RNA-mediated gene silencing        21 
Biotinylation and immunoprecipitation         22 
Western blotting           22 
Cell motility           22 
Cell adhesion           23 
T-cell activation           23 
  
 
STATISTICAL ANALYSES          24 
 
RESULTS           25 
 
STUDY I           25 
STUDY II           27 
STUDY III           33 
STUDY IV           36 
 
DISCUSSION           38 
 STUDY I           38 
 STUDY II           39 
 STUDY III           40 
 STUDY IV           42 
 
 
    CONCLUSION           43 
 
    FUTURE PERSPECTIVES          44 
 
    POPULAR SCIENCE          45 
 
    ACKNOWLEDGEMENTS          46 
 
    REFERENCES           48 
 
  
  
LIST OF ABBREVIATIONS 
 
 
Th1 
Th2 
Th17 
Treg 
CD 
 
 
Type 1 T helper cells 
Type 2 T helper cells 
Type 17 T helper cells 
Regulatory T cells 
Cluster of differentiation 
IFN  
TNF-α  
IL 
GM-CSF 
MHC 
PD 
RANKL 
TLR2 
TCR 
BCR 
GAG                            
DC  
NK                               
HLA                             
MHC                            
T2D 
ACPA                        
CSF                             
M-CSF                        
FGF                           
HGF                            
EGF                             
PDGF                          
IGF                             
NGF                            
APC  
EDTA  
NLRP3                                                   
                            
 
 
Interferon 
Tumor necrosis factor alpha 
Interleukin 
Granulocyte macrophage - colony stimulating factor 
Major histocompatibility complex 
Periodontal disease 
Receptor activator of nuclear factor kappa-Β ligand 
Toll-like receptor 2 
T cell receptor 
B cell receptor 
Glycosaminoglycan 
Dendritic cell 
Natural killer cell 
Human leukocyte antigen 
Major Histocompatibility Complex 
Type 2 diabetes      
Anti-citrullinated protein antibody  
Colony stimulating factor 
Macrophage-colony stimulating factor 
Fibroblast growth factor 
Hepatocyte growth facto 
Epidermal growth factor 
Platelet derived growth factor 
Insulin-like growth factor 
Nerve growth factor 
Antigen presenting cell  
Ethylenediaminetetraacetic acid 
Nucleotide-Binding Oligomerization Domain, Leucine Rich 
Repeat and Pyrin Domain Containing 3 
 
  
  
 
 1 
 
INTRODUCTION 
 
Inflammation 
Inflammation is a special state in terms of tissue response to injury that causes a shift in its metabolic status 
from an anabolic towards a catabolic one. In the strictest sense, these characteristics differ from that of a tissue 
degenerative process firstly, by the rate with which catabolism exceeds anabolism and, secondly, the rise in the 
osmotic pressure causing significant fluid accumulation. Therefore, inflammation is almost a pathological 
process arising as a direct consequence of a tissue insult or injury. To counterbalance it, an opposing reactive 
process, the anti-inflammatory response, is characterized by proteolysis inhibition (Hiemstra, 2002). 
In a healthy state, after inflammation reaches its maximum capacity, an anti-inflammatory response ensues to 
restore tissue homeostasis, representing a true defensive response (Table 1). Thus, inflammation ensued by an 
anti-inflammatory response is vital for complete healing which, if not the case, can develop into chronic 
inflammation and autoimmune diseases (Stankov, 2012). 
 
Table 1. Contrasting features of inflammation and anti-inflammatory process* 
 
*adapted from (Stankov, 2012). 
** Not yet known 
 
 
 
Acute inflammation 
Based on onset and duration, inflammation can be categorized into acute and chronic. Acute inflammation is 
characterized by a rapid onset, short duration, and profound signs and symptoms.  
Acute inflammation occurs through several stages that are recognized through cellular changes. Initially, there 
is an increase in blood flow within and around the vasculature at the site of injury. An increase in vascular 
permeability allows recruited immune cells extravasate into the injured parenchyma where they migrate to the 
injured cells using gradients of inflammatory molecules via chemotaxis. Upon reaching the site of injury, 
immune cells proceed to phagocytose microbes and cellular debris which may be present (Rubin et al., 2009).  
The ultimate goal of the acute inflammatory response is clearance of damaged host cells and removal of 
pathogens. However, some recruited immune cells such as macrophages and dendritic cells travel to local 
lymph nodes where, as APCs, they process and present degraded phagocytosed debris advancing the immune 
response from that of an innate to an adaptive one.  
 
 
 
Inflammation Anti-inflammatory response 
Stimulated catabolism Catabolic inhibition 
Hypoxia NYK** 
Hyperosmolarity NYK 
Immediate-transient venular response NYK 
Edema formation Edema resolution 
Necrosis Apoptotic cell clearance 
Lysis of colloids NYK 
Immunostimulation NYK 
 2 
 
 
Some of the key features of acute inflammation, which aim to culminate in the formation of an exudate, are 
brought about by several bioactive molecules. The most profound effects are on vasculature and leukocyte 
recruitment (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A simplified overview of the inflammatory mediators involved in the key features of acute 
inflammation (Medzhitov, 2008). 
 
 
 
Chronic inflammation  
In contrast, chronic inflammation is slow in onset and longer in duration with variable intensity of signs and 
symptoms. Chronic inflammation can follow acute inflammation, but it can also occur as a symptomless low-
grade, prolonged response to an inciting agent.  
A transition to a pattern of chronic inflammation develops following weeks of an unresolved inflammatory 
process. This is associated with a shift in the demographic of immune cells at the site of injury. 
The prime feature of chronic inflammation is the prominent presence of monocyte/macrophages, lymphocytes, 
plasma cells, fibroblasts and vascular endothelial cells at the site of injury (Rubin et al., 2009). For 
inflammation to be resolved, an active process of resolution must be brought about via the biosynthesis of pro-
resolving mediators which can modulate key events of inflammation in order to restore tissue homeostasis 
(Serhan et al., 2008).  
 
 
Autoimmunity and autoinflammation 
Autoimmunity can be described as self-directed injury, whereby B and T cell responses in primary and 
secondary lymphoid organs lead to breaking of tolerance. This results in a strong immune reactivity towards 
self-antigens. Organ-specific pathologic autoantibodies may predate clinical disease expression by years 
before tissue damage is evident. Most autoimmune diseases have an inflammatory component with effector 
mechanisms that involve CD4 T cell subpopulation (Th1, Th2, Th17, Treg, Th9 and Th22) (Ivanova et al., 
2015). According to recent studies, several cytokines (IFN, TNF-α, IL-1ß, IL-10, IL-13, IL-17, GM-CSF) are 
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involved in the pathogenesis of systemic lupus erythematosus, polymyositis, rheumatoid arthritis and systemic 
scleroderma (Higgs et al., 2012). 
Autoinflammatory diseases are clinically manifested conditions marked by abnormally increased inflammation 
mediated by cells and molecules of the innate immune system. The dysregulation mainly involves the failure 
to process and control the secretion of cytokines IL-1β and IL-18. This is related to mutations in NLRP3, a 
component of a macromolecular complex known as the inflammasome. The inflammasome mediated 
activation of caspase-1 is responsible for IL-1β and IL-18 processing (Hoffman and Broderick, 2016). 
Recently, some evidence has shown that the same pathogenetic mechanism responsible for the activation of 
innate immunity in inherited autoinflammatory diseases may also play a key role in sustaining inflammation in 
several multifactorial illnesses, such as T2D (Ciccarelli et al., 2014). Typically, autoinflammatory diseases 
have no associations with HLA or MHC class II haplotypes, and there is an absence of autoreactive T cells or 
autoantibodies (Shaw et al., 2011, Doria et al., 2012). 
 
Periodontal inflammation 
Most inflammatory diseases of the oral cavity involve the tissues of periodontium. The teeth emerge into the 
oral cavity after crossing bone and connective tissue as well as epithelial tissues. In the environment of the oral 
cavity, these hard structures are surrounded by a biofilm comprising of a vast collection of bacteria known to 
exist outside the colon. Such an architectural arrangement of soft and hard tissue compartments may or may 
not act jointly during the inflammatory responses. 
The two common diseases affecting the health of the periodontium are gingivitis and PD. Gingivitis, or 
inflammation of the gingiva, is limited to the soft tissues comprising of epithelial and connective tissue. The 
inflammatory changes in gingivitis are reversible with adequate hygiene measures. In the case of periodontal 
disease, the inflammatory process involves the periodontal ligament and alveolar bone. The progression from a 
reversible gingivitis to an irreversible loss of bone and ligamental tissues around the tooth has been described 
in terms of histopathological stages (Page and Schroeder, 1976). With the passage of time, the description was 
modified. The histopathological description is shown in Table 2 (Kinane and Lindhe, 1997). 
Periodontal health is likely to be challenged by a dysbiotic oral microbiota but ultimately, periodontal 
destruction is the result of a dysregulated immune response. 
 
Role of immune cells in periodontal disease 
In healthy periodontal tissues, local immunity is orchestrated by the presence of antigen presenting cells 
(macrophages and dendritic cells), T lymphocytes (mostly CD4-positive helper T lymphocytes), and a 
comparatively lower number of neutrophils, B-cells and plasma cells. During inflammation, an increase is seen 
in most of these cells.  
 
Neutrophils comprise of >95% of leucocytes in the gingival crevice. Co-ordinated and regulated recruitment 
of neutrophils is vital to periodontal health. In patients with PD, neutrophils have shown decreased 
chemotactic accuracy and propensity towards increased secretion of pro-inflammatory cytokines including 
membrane bound RANKL, CCL2 and CCL20 which recruit Th17 cells and APRIL, a B-cell stimulator and 
proliferation-inducing ligand (Chakravarti et al., 2009,  Pelletier et al., 2010).  
 
Macrophages are present in low numbers in healthy periodontal tissues, however they have been shown to 
positively correlate with the extent of collagen breakdown in PD (Younes et al., 2009, Seguier et al., 2001). 
They have also been detected in deep periodontal pockets and sites associated with disease progression (Allam 
et al., 2011). Few studies have demonstrated that TLR2 signaling in macrophages is crucial for TNF-alpha-
dependent osteoclastogenesis (Ukai et al., 2008). Macrophages have a role in the resolution of inflammation 
mainly by removing apoptotic neutrophils (efferocytosis) (Ortega-Gomez et al., 2013). This may be a 
compromised mechanism in PD pathogenesis since PD is a chronic disease in which inflammation is not 
resolved in a timely manner. 
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T lymphocytes can be polarized into distinct T-helper cellular subsets upon activation by APCs (Figure 2). 
The balance between functional T cell subsets is crucial for maintaining homeostasis. Several studies in 
humans show Th1 cells are associated with stable lesions whereas advanced or progressive lesions are 
associated with Th2 cells in PD but this dichotomy was too simplistic to clarify PD pathogenesis. Tregs are 
strong inhibitors of osteoclast formation but under inflammatory conditions, the immuno-suppressive functions 
of these CD4 Tregs are diminished by the abundance of pro-inflammatory cytokines (Valencia et al., 2006). 
These CD4 Tregs are present in low numbers in the gingival tissues of subjects with PD where some may 
switch to Th17 phenotype (Okui et al., 2010). The role of Th9 and Th22 subsets have not been studied as 
extensively in PD, however IL-22 has been linked to disease severity and bone loss (Díaz-Zúñiga et al.,2017). 
Recent studies regarding Th cells have revealed that these cells are neither inflexible nor strictly committed but 
rather exhibiting ‘plasticity’ in their phenotype as dictated by conditions activated by different cytokines 
(O’Shea and Paul, 2010).  
 
 
Table 2. Clinical and histopathological stages of periodontal disease 
*adapted from Kinane and Lindhe, 1997. 
 
 
 
 
 
Clinical 
condition 
Time 
(days) 
Histopathological condition 
Pristine gingiva - Little or no inflammatory infiltrate 
Normal healthy 
gingiva 
4 days Initial lesion:  
 vasculitis below junctional epithelium (JE) 
 exudation of fluid into connective tissues and gingival sulcus 
 increased migration of neutrophils and leucocytes 
 increased perivascular collagen loss 
Early gingivitis 7 days Early lesion 
 accumulation of lymphoid cells below JE 
 cytopathic changes in resident fibroblasts 
 further loss of collagen 
 early proliferation of basal cells of the junctional epithelium 
Established 
gingivitis 
21 days Established lesion 
 increase in plasma cells 
 presence of immunoglobulins in the connective tissues, JE and 
gingival crevice 
 continued loss of collagen fibers and fibrous CT matrix 
 proliferation, apical migration and lateral extension of the JE 
 
Periodontal 
disease 
- Advanced lesion  
 persistence of features in established lesion 
 formation of periodontal pocket 
 significant bone loss 
 loss of periodontal ligament 
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Figure 2. T lymphocyte subsets functions and roles in PD. Differentiation of naïve CD4 T cells into 
different types of T helper subsets (Th) or inducible regulatory T cells (T regs) and their roles in periodontal 
disease (PD). APC = antigen presenting cell. 
(Okui et al., 2014, Díaz-Zúñiga et al., 2017). 
 
 
B lymphocytes 
In established periodontal lesions, there is a clear dominance of B- lineage cells, comprising of up to 60% of 
the total leukocyte infiltrate (Thorbert-Mros et al., 2015). In severe PD, tissue samples show B lymphocytes 
predominating over plasma cells and T lymphocytes. A majority of these B lymphocytes were found to 
express CD5 (Donati et al., 2009).  The presence of high numbers of B lymphocytes in PD lesions seems to be 
linked to polymicrobial antigenic stimulation within the oral biofilm. To contravene this antigenic challenge, 
local B lymphocytes are likely to be induced and activated via both T dependent and T independent pathways. 
The role of B cell antibody response in PD is still not clear as studies have shown that subjects with high 
antibody titers against P. gingivalis have more severe alveolar bone loss. This may be attributed to the 
antibody response in PD being of low affinity (Whitney et al. 1992, Kinane et al.. 1999).  
 
Osteoclasts 
Osteoclasts (OCs) can be described as specialized polykaryons that belong to the macrophage lineage (Boyle 
et al, 2003). Both mature OCs and osteoclast precursors respond to inflammatory cytokines as part of 
regulation by the immune system. They are, therefore, immune cells. It has been shown that in common with 
other cells of the immune system, osteoclasts also share a requirement for costimulatory signals that are 
mediated by immuno-receptor tyrosine-based activation motifs (ITAMs) (Koga et al., 2004). In osteoclasts, 
this co-stimulation is needed for RANKL-induced differentiation followed by bone resorption (Koga et al., 
2004). Like innate immune cells, OCs express the inflammasome complex as well. OCs are formed from the 
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fusion of from peripheral blood-borne mononuclear cells that arise from precursor cells in the bone marrow. 
These cells are the same mononuclear precursor cells as macrophages and dendritic cells (DCs), therefore it 
has been demonstrated in vitro that OCs can act as functional APCs as they expressed MHC molecules (HLA-
ABC and HLA-DR), costimulatory molecules (CD80, CD86, and CD40) and that the expression of these 
molecules could be up-regulated by IFN-γ. They also play a role in bone formation by releasing cellular 
products, termed as ‘clastokines’, which are capable of stimulating osteoblast bone formation. OCs have a vital 
role in the pathogenesis of PD since bone loss is a hallmark of this disease. The OC precursors circulate in 
blood, extravasate and settle in the bone, promptly diﬀerentiating into OCs in the presence of M-CSF and 
RANKL (Muto et al., 2011). A recent study showed via nucleoside labelling of precursor cell nuclei that > 
90% of OCs found in ligation induced PD were derived from OC precursors formed before the induction of 
PD (Lee et al., 2015). 
 
 
Cytokines, chemokines and growth factors 
Inflammation is controlled by a host of extracellular mediators and regulators which include cytokines, 
chemokines and growth factors. 
Cytokines are cellular messengers that are highly active within the environment of their cellular source(s). 
Structurally, they are synthesized as either proteins, glycoproteins or polypeptides. Majority of them have 
immunologically modifying effects. They are mostly secreted but may also be expressed on the cell 
membrane. There are no structural differences between cytokines bound to cell membranes and those that are 
secreted. The membrane-bound cytokines can be cleaved at the extracellular part by metalloproteases and, 
therefore, secreted. However, their secretion is not continuous in nature as they are mostly produced in 
response to cell activation. The efficacy of cytokines as cellular messengers is established through an 
interaction with their receptors which results in a signal transduction that results in a fast or a slow action on 
the target cell. Chemokines are an excellent example of fast action inducing signal transduction. They are 
cytokines which are involved in chemotaxis, a process of attracting cells to a specific site via establishment of 
a chemically stimulating gradient. This is a vital process in an immuno-inflammatory response for controlling 
leukocyte trafficking. Most chemokines bind to several receptors and each chemokine receptor can bind more 
than one ligand. Based on their primary structure, there are four families of receptors (R): XCR, CCR, CXCR, 
and CX3CR (X stands for any amino acid; C denotes cysteine). The chemokine ligands (L) are separated into 
four groups: XCL, CCL, CXCL, and CX3CL (Dembic, 2015). 
 
Cytokines which influence growth and tissue regeneration can be classified according to the extent of their 
influence such as those on:  
1. Single line of cells:  CSF, G-CSF, M-CSF, GM-CSF. 
2. Specific tissues: FGF, HGF, EGF, PDGF, IGF, NGF. 
3. All tissues: TNF-α ,TNF-β and TGF-β (Dembic, 2015). 
 
Cytokines play an important part in the host response to PD as they have putative roles in terms of tissue 
destruction or protection (Figure 3).  
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Figure 3. Cytokines and their documented response in periodontal inflammation (Garlet et al., 2012). 
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T lymphocyte regulation 
An effective T cell immune response requires an antigen-specific signal through the TCR along with 
simultaneous antigen non-specific signaling via a co-stimulatory receptor. T cells migrate to the periphery and 
enter the naive T cell pool after undergoing a selection check in the thymus. In the periphery, naive T cells are 
continuously recirculating between secondary lymphoid organs and blood through the lymphatic system. In 
terms of function, these cells have yet to encounter their associated antigen which, upon doing so, will cause 
them to differentiate and proliferate into effector or memory T cells. Effector T lymphocyte motility, adhesion, 
and activation depend on certain factors which would prevent it from being activated under transient adhesive 
interactions (van den Broek et al.,2018, Lui Z et al., 2009). 
 
T regs are specialized cells for suppressing immune responses towards self and non-self-antigens. Mature T 
regs can be induced in the periphery but the majority of circulating Tregs are generated in the thymus. T regs 
express Foxp3 which is a transcription factor required for the differentiation of a TCR positive T cells into T 
reg cells. T reg mediated suppression comprises of secretion of immunosuppressive cytokines, and 
modification or killing of APC. Although self-reactive T cells are deleted in the thymus and the periphery, 
sometimes elimination is not carried out completely. This then requires immune suppression mechanisms to 
keep auto reactive T cells in check. Specialized cells and/ or cytokines are major elements of this actively 
carried out immune suppression. Also known as inhibitory immune receptors, immune checkpoints serve as 
negative regulators of the immune response, thereby protecting the host from excessive inflammation.  
Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed cell death protein1 (PD1) are known 
immune checkpoints. CTLA-4 competes with co-stimulatory molecule CD28 for co-stimulatory ligands and 
attenuates the early activation of naive T cells. PD1 directly interferes with TCR signaling and can inhibit T 
cells at the effector stage. The expression of PD1 has been associated with T cell exhaustion and has been 
shown to be expressed by gingival CD8 T cells (Figueira et al., 2009). CTLA-4 being a crucial Treg related 
molecule, has been shown to be expressed by only a small number of cells in periodontal lesions (Orima et al., 
1999).  
 
The importance of transforming growth factor-beta (TGF-β) in T cell regulation is immense due to its ability to 
stimulate naive T cells to differentiate into Tregs. The differentiation takes place via the induction of Foxp3 
expression allowing them to acquire regulatory roles which comprise of suppressing effector T cell 
proliferation and function. TGF- β is a pleiotropic cytokine known to suppress genes involved in T-cell 
differentiation and function. It can also suppress the production of pro-inflammatory cytokines and stimulate 
T-cell production of IL-10 (Kitani et al., 2003, Johnston et al., 2016).  
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EPIDEMIOLOGY OF PERIODONTAL DISEASE 
  
 
Prevalence of PD 
Severe PD was reported to have an age-standardized global prevalence of 7.4% in 2015 (Kassebaum et al., 
2017). In an earlier report on the global burden of diseases, severe PD was the sixth most prevalent disease 
amongst 291 diseases (Murray et al., 2012). The global burden of PD has increased by 74.9% from 1990 to 
2015 becoming the leading cause of tooth loss in adults (Kassebaum et al., 2017).  As a result, it contributes to 
edentulism and masticatory dysfunction (Petersen and Ogawa, 2012). Southeast Asia is also one of the regions 
which has severe PD as the leading cause of disability adjusted life-years (DALYs) (Marcenes et al., 2013).  
Some studies have reported a prevalence ranging from 60 to 100 % (Shaju et al, 2011). According to the WHO 
oral health situation analysis of Pakistan, an astounding 93% of individuals above the age of 65 have 
periodontal disease (Khan et al., 2004).  
 
Risk assessment for PD 
In order to assess the likelihood for an individual to develop PD, factors, determinants and predictors are 
important in identifying ‘potential risk’. A risk factor is an environmental exposure, an aspect of personal 
behavior or inherited characteristics which are known to be associated with a health related condition. Risk 
factors can be classified as modifiable or non-modifiable. Modifiable risk factors are environmental or 
behavioral in nature whereas non-modifiable risk factors are intrinsic to the individual and therefore not 
changeable.  Risk determinants are non-modifiable risk factors. Risk predictors are clinical or biological 
markers indicative of disease progression with no etiological relationship to the disease (Figure 4) (Last et al., 
2001, Van Dyke and Dave, 2005). Table 3 shows the literary evidence for factors, determinants and predictors 
of risk associated with PD development. 
 
 
 
 
 
 
 
Figure 4. Risk factors, determinants and predictors implicated in periodontal disease development. 
 
 
 
Risk factors
Smoking
Diabetes
Socioeconomic
status
Inflammophilic 
pathobionts
Risk 
determinants
Age
Ethnicity/
Race 
Genetics
Risk 
predictors
Number of sites 
≥ 5mm probing
Reduced 
marginal bone 
level
Serological 
markers (?)
 10 
 
 
Table 3. Evidence for the role of risk factors, determinants and predictors in periodontal disease 
 
 
 
Smoking  Associated with increased alveolar bone loss, development of periodontal 
pockets and tooth loss (Bergström et al., 1994).  
 Cumulative effect of longer duration of smoking resulting in greater periodontal 
destruction (Grossi et al.,1995).  
 Periodontal therapy in smokers is associated with less reduction in probing 
depth and smaller gains of clinical attachment than in nonsmokers (Patel et al., 
2012, Jin et al., 2000). 
Diabetes  Higher prevalence and severity of periodontal disease in patients with type 1 
and type 2 diabetes (Hodge et al.,2012, Taylor et al., 2010).  
 Relative risk of incidence of periodontal disease is 2.6 (95% confidence 
interval: 1.0–6.6) in patients with type 2 diabetes compared with people without 
diabetes (Nelson et al., 1990). 
 Severity of periodontal conditions is increased in poorly controlled diabetics as 
compared to pre-diabetics (Altamash et al., 2013).  
 Treatment of periodontal disease results in consistent reduction in glycated 
hemoglobin (Altamash et al., 2016, Simpson et al., 2010) . 
Socioeconomic 
status 
 Social hierarchies create levels of psycho-social stress which are manifest in 
health gradients (Wilkinson et al., 1999).  
 SES variables account for ~50% of the differences in PD prevalence at 35-44 
years of age (Hobdell et al., 2003). 
 Distinct pattern of health-related behavior, knowledge and health attitudes 
reflect differences in periodontal health (Peterson, 1990). 
Inflammophillic 
pathobionts 
 Alteration of the periodontal microbiota from a symbiotic to a dysbiotic state in 
a susceptible host (Hajishengalis, 2014a). 
 Presence of keystone pathogens such as P. gingivalis can shift the host- microbe 
homeostatic balance toward dysbiosis (Hajishengalis et al., 2011). 
 Host tissue inflammation allows growth of ‘inflammophilic’ bacteria that thrive 
and contribute to further pathogenesis (Abusleme et al., 2013, Hajishengalis, 
2014b ). 
 
Age  Increasing age associated with an increase in the prevalence, extent and severity 
of periodontal attachment loss (Eke et al., 2012, Machtei et al .,1999). 
 The rate of radiographic alveolar bone loss increases in the third to fifth decades 
(Grossi et al.,1995).  
Ethnicity and sex  Ethnicity seems to be associated with periodontal disease,  possibly through 
socioeconomic linkage (Borell & crawford, 2012).  
 Greater risk for destructive periodontal disease in men than women (Shiau & 
Reynolds, 2010). 
Genetics  Familial aggregation studies reveal that PD in young individuals has a stronger 
genetic link (Meng et al., 2011). 
 Polymorphisms in the interleukin-1, interleukin-6, interleukin-10 and CD14 
genes are restricted to certain populations (Laine et al., 2010). 
 Epigenetics play a role in PD (Martins et al., 2015). 
Pocket depth  Number of sites with deep pockets (≥ 5mm) are risk predictors for progression 
of PD (Van der Velden et al., 2006). 
Marginal bone 
loss 
 Reduced marginal bone level in younger individuals represents higher risk of 
further bone loss (Bahrami et al., 2007). 
Serological 
markers 
 Presence of periodontal disease related to high systemic inflammatory protein 
levels (Dye et al., 2005). 
 Serum CRP, IL-6 , Oncostatin M, MMP-8 and MMP-9 have been identified as 
biomarkers with great potential for monitoring response to periodontal disease 
progress (Stathopoulou et al., 2015). 
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Periodontal Parameters 
 
PD parameters comprise of bleeding on probing, probing pocket depth and radiographic findings (American 
Academy of Periodontology Task Force Report. 2015). 
 
Plaque/ Oral biofilm 
The microbial biofilm has been extensively studied, identifying up to 800 different species in human dental 
plaque so far (Lourenco et al., 2014). The presence of plaque can induce inflammatory changes in the gingiva 
leading to noticeable symptoms that include gingival swelling, redness and bleeding with tooth brushing and 
chewing. Its presence in abundance is an important parameter to identify in terms of therapeutic intervention 
(Murakami et al., 2018). 
 
 
Bleeding on probing 
In order to assess the state of gingival tissues, BOP is used as a clinical parameter. BOP is measured as 
bleeding provoked by inserting a probe to the bottom of a pocket. The absence of BOP is a clinical indicator of 
periodontal health or stability following periodontal therapy (Lang and Bartold, 2018). 
 
 
Periodontal Pocket depth  
The space found between a pathologically deepened gingival sulcus around a tooth is known as a periodontal 
pocket (Bosshardt, 2018). Increased depth of the periodontal pocket is a clinical finding that reflects 
breakdown of periodontal fibers, loss of cementum and bone. It is important to describe the biological 
significance of periodontal probing. Under healthy conditions, the lateral wall of the gingival crevice is lined 
by the sulcular epithelium in the coronal part and the junctional epithelium in the apical part and measures 
0.5mm (Bosshardt, 2018). The junctional epithelium lines the bottom of the sulcus in the region of the 
cemento-enamel junction (Mombelli, 2005). Probing is performed to delineate the depth of the pocket, 
measured in millimeters, by passing a narrow-diameter probe gently, but firmly, between the tooth and 
gingiva.  
 
Radiography 
Radiographs provide information regarding bone level and bone loss that cannot be gained through clinical 
examination. The position of the alveolar bone crest is imaged for estimation of the degree of bone loss. 
Information regarding the pattern of bone loss, either vertical or horizontal, can also be gained from 
radiographs (Hirschmann, 1989). The normal position of alveolar bone crest lies within 2 mm from the 
cemento–enamel junction as a diagnostic threshold (Hansen et al., 1984, Hausmann et al., 1991). 
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RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease influenced by both genetic and 
environmental factors (Angelotti et al., 2017). In confirmed cases of RA, the course of disease can vary from 
slowly progressing and overall mild disease, remaining a predominantly local condition to aggressively 
progressive with multiple joint involvement and erosion with systemic involvement (Forslind et al., 2004). 
There is no known etiological factor for RA, however genetic susceptibility plays a significant role 
(Malmström et al., 2017). 
 
EPIDEMIOLOGY  
Most epidemiological studies in RA have been done in Western countries, showing a prevalence of RA in the 
range of 0.5–1.1% (Tobón et al., 2010). In the city of Karachi, Pakistan, the prevalence of RA is reported to be 
0.14% as compared to that of northern Pakistan where the estimated prevalence is 0.55% (Hameed et al., 
1997). 
 
 
Risk factors 
 
Genetics: RA has a strong genetic component where the phenotypic variance due to genetic variance is 
~60% (MacGregor et al., 2000). This is mostly seen in RA patients who are positive for anti-CCP antibodies, 
whereas estimates in seronegative disease are lower (Padyukov et al., 2011, Viatte et al., 2016).  
Specific genetic loci show a very strong association with RA (Gregersen et al., 1987). These are MHC (also 
known as HLA) molecules that may contain the shared epitope which is a specific amino acid motif commonly 
encoded by alleles of the HLA‑antigen D related (DR) locus. Alleles known to be associated with the risk of 
developing RA are HLA‑DRB1*01 and HLA‑DRB1*04 (Weyand et al., 1992).  
 
Epigenetics: The genetic risk associated with HLA variants is partly due to epigenetic changes that entail 
altered DNA methylation (Liu et al., 2013). Environmental factors can induce changes in cellular function 
through DNA methylation. 
 
Smoking: The association between tobacco and RA is strongest in anti-CCP positive individuals with at least 
one copy of the shared epitope. Interaction between the shared epitope and smoking causes a 20 fold greater 
risk of developing RA as compared to non-smokers (Källberg et al., 2011).Smoking status is also an important 
factor as current smokers have increased levels of pro-inflammatory cytokines and higher disease activity 
(Sokolove et al., 2016).  
 
Ethnicity and sex: RA clinical manifestations tend to vary between ethnic groups. This may be explained 
by ethnic variation in terms of the frequency and types of HLA–DRB1 alleles containing the SE (del Rincón et 
al., 2003). In terms of gender predilection, the cumulative risk of developing RA is twice as high for women as 
compared to men (3.6% for women versus 1.7% for men) (Crowson et al., 2011). The stimulatory and 
regulatory effects of estrogen in localization of Th17 cells during the development of arthritis on the immune 
system might account for sex as a risk factor (Andersson et al., 2015).  
 
Microbiota: Porphyromonas gingivalis is a resident microbe in the subgingival sulcus of the oral cavity. It 
requires energy from the fermentation of amino acids (Bostanci and Belibasakis, 2012). Research focused on 
this opportunistic pathogen has postulated an etiological role in the development of RA, specifically in anti-
citrullinated protein/peptide antibody positive patients (Rosenstein et al., 2004). This is based on its unique 
property to express a citrullinating peptidylarginine deiminase (PAD) enzyme. The PAD enzyme is capable of 
converting arginine residues in proteins to citrulline which consequently alters protein structure and function. 
Aside from periodontal microbiota, the gut microbiota in new-onset, DMARD naive RA patients had a 
significantly higher abundance of Prevotella copri (Scher et al., 2013). In a recent study, peptides of two novel 
autoantigens were isolated from HLA-DR molecules of patients with RA that shared the sequence homology 
with peptides of Prevotella and other gut bacterial species (Pianta et al., 2017). Apart from bacteria, the 
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Epstein–Barr virus (EBV) infection has also been associated with RA as there are reports demonstrating that 
EBV load is almost 10-fold higher in RA patients than in healthy controls (Balandraud et al., 2003). 
 
 
Clinical diagnosis 
Early RA is characterized by synovial inflammation based on mononuclear cell infiltration, with increased 
CD4 positive T cells and macrophage activation. The autoimmune response triggers synovial inflammation 
inducing cytokine production and increased synovial vascularity perpetuating the disease and ultimately 
causing joint destruction (Figure 5). 
Diagnosing RA is an individualized process solely based on the interpretation of the rheumatologist. In the 
absence of standardized diagnostic criteria, classification criteria that include clinical manifestations and 
serological assays (autoantibody and acute-phase protein levels) help inform clinical diagnosis. 
 
Serology  
Autoantibodies to IgG (rheumatoid factor or RF) and cyclic citrullinated proteins (anti-CCP) are an important 
characteristic of RA (seropositive RA), but not for all individuals, as some are negative for these 
autoantibodies (seronegative RA). This may be seen as a major drawback for these two biomarkers since they 
cannot be detected in seronegative RA cases. Compared with anti-CCP, RF presents higher sensitivity for 
established disease, with a relatively low specificity. The combination of RF and anti-CCP assays approach a 
positive predictive value of ~100 %, which is much higher than the value of either of the tests alone (Taylor et 
al., 2011). The presence of both RF and anti-CCP have been associated with progressive disease (Syversen et 
al., 2008). 
 
 
Joint involvement 
The joints involved in RA include the metacarpophalangeal joints, proximal interphalangeal joint of the hands 
and feet, wrist, ankle, elbow, shoulder, knee and hip joints (Smolen et al., 1995). The high inflammatory nature 
of RA causes articular cartilage and periarticular bone degradation. 
 
 
Systemic and extra articular manifestations 
RA is associated with an increased acute-phase response which can lead to a number of extra-articular 
manifestations over a period of time. Second to cardiovascular disease, interstitial lung disease is one of the 
most severe extra-articular manifestations of RA. RA may additionally be accompanied by secondary Sjögren 
syndrome, secondary amyloidosis or lymphoma (Smolen et al., 2018). 
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Figure 5. Cytokines and their role in rheumatoid arthritis (McInnes and Schett, 2007). 
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CLASSIFICATION CRITERIA     
Classification criteria are standardized definitions that are intended to identify the majority of 
patients with key features of the condition shared amongst them for research purpose. The 
goal of classification criteria therefore differs from that of diagnostic criteria (Aggarwal et al. 
2015). The current classification criteria are those by the American College of Rheumatology 
(ACR) and the European League against Rheumatism (EULAR) established in 2010. The 
ACR/EULAR 2010 criteria have been developed for a population of individuals presenting 
with at least one clinically swollen joint which cannot be explained by any other disease 
(Aletaha et al, 2010). 
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AIMS OF THESIS 
 
 
 
GENERAL AIM 
The general aim of this thesis was to investigate the systemic inflammatory burden in 
subjects with periodontal disease, with special emphasis on host immuno-inflammatory 
responses in terms of inflammatory, immunological and exploratory markers.  
 
SPECIFIC AIMS 
 
Study I  
To show that T cell motility, adhesion, and activation depend on the large transmembrane cell 
surface receptor low-density lipoprotein receptor-related protein 1 (LRP1) and its ligand 
thrombospondin-1 (TSP-1).  
Study II  
To investigate serum cytokines, chemokines, growth factors, enzymes and costimulatory 
proteins in association with periodontal conditions in PD and RA subjects. 
Study III  
To investigate the serum markers receptor activator of nuclear factor‐kappa B ligand 
(RANKL), osteopontin (OPN), tumor necrosis factor receptors 1 (TNFR1) and 2 (TNFR2), 
osteoprotegerin (OPG) and RANKL/ OPG ratio and compare them in PD and RA groups. 
Study IV  
The aim of this study was to investigate the severity of both PD and RA and investigate 
correlation between glycemia and periodontal disease parameters using a PPD Total index. 
 
 
 
ETHICAL CONSIDERATIONS 
The research project was approved by the ethics committee of the Altamash institute of 
Dental Medicine, Karachi, Pakistan and the Regional Ethical Review Board in Stockholm, 
Sweden. It was conducted in accordance with the Declaration of Helsinki. An informed 
written consent was obtained in the native language Urdu and English as per requirement, 
from all participants. 
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MATERIAL AND METHODS 
 
Patients 
In study II and III, 38 patients suffering from RA were included (mean age ± SD: 46.1 ± 11.9 
years). In study IV, a total of 47 RA patients were included (mean age ± SD: 46.1 ± 11.2 
years) as shown in Table 4. They were referred from the Department of Rheumatology at 
Habib Medical Centre, Karachi, Pakistan. 
The number of subjects with PD were 38 in study II and III (mean age ± SD: 47.4 ± 9.3 
years). In study IV, a total of 51 subjects were included (mean age ± SD: 47.9 ± 9.5 years) 
(Table 4). Inclusion criteria: 18 years and above in age. Exclusion criteria: individuals 
suffering from osteoarthritis, gout, and/ or treatment with antibiotics in the last three months 
and / or undergoing treatment for periodontal disease during the last six months were 
excluded. Edentulous persons were excluded. 
 
 
Healthy individuals 
Healthy individuals attending the Altamash Institute of Dental Medicine were selected as 
controls. In study II and III, 14 healthy controls were included (nine males and five females, 
range: 35 to 60 years; mean age ±SD: 44.4 ± 6.6 years). For study IV, a total of 20 controls 
were included (12 males and eight females, mean age ±SD: 43 ± 6.3 years). The selection 
criteria for controls was absence of PD and systemic disease. 
 
 
Table 4. The number of subjects in RA and PD groups for studies II, III and IV 
 
 
Cells 
For study I, human blood lymphocytes from healthy volunteers at Huddinge University 
Hospital were used after purification using Lymphoprep. Monocytes and phagocytic cells 
were treated with carbonyl iron and removed magnetically. The use of lymphocytes from the 
blood of healthy individuals was approved by the local ethics committee. The cell 
preparations consisted of 82–93% CD3-positive cells. T cells were further enriched and 
purified by depleting CD56-, CD19- and CD14- positive cells using beads coated with the 
corresponding antibodies. Lymphocytes were cultured in RPMI-1640 supplemented with 2 
mM L-glutamine, 0.16% sodium bicarbonate, 10,000 U/ml benzylpenicillin, 10,000 µg/ml 
streptomycin and 10% fetal calf serum or in serum-free AIM-V medium. The experiments 
Patients with RA Total  Females  Males 
Study II and III 38 33 5 
Study IV 47 41 6 
Patients with PD only Total  Females  Males 
Study II and III 38 26 12 
Study IV 51 33 18 
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were performed under serum-free conditions in order to exclude any interference of 
exogenous proteins and peptides. 
 
QUESTIONNAIRE 
For study II, III and IV, a questionnaire was used to collect information from participating 
subjects regarding presence of self-reported chronic diseases and previous hospitalization 
history. Detailed information regarding oral health status, past dental history, oral hygiene 
measures, use of medication and smoking habits were recorded. Medical records and 
prescription for medication was requested for verifying self-reported conditions. 
 
PERIODONTAL EXAMINATION 
A detailed periodontal examination was carried out for all participating subjects in study II, 
III and IV at the Department of Periodontology, Altamash institute of Dental Medicine, 
Karachi, Pakistan. The examination comprised of recording plaque index (PI), bleeding on 
probing (BOP) and periodontal probing depth (PPD) for all teeth excluding third molars. The 
indices recorded four sites per tooth. Periodontal disease was defined as three sites or more in 
three different teeth with PPD of ≥5mm. For pocket measurement, Hu Friedy’s Goldman-Fox 
probe was used. BOP was recorded as present or absent within 30 seconds of probing. The 
scores were recorded as a mean percentage for PI and BOP and as number of pockets 
measuring PPD 3-<5mm and PPD ≥5mm. For study IV, the total cumulative pocket depth 
was used as a continuous variable. The number of missing teeth was also recorded. 
Embedded root remnants of teeth were considered as missing. 
Additionally, a novel index was derived by adding the probing pocket depth measurements 
from all measured sites to give a total aggregate whose value is the sum of each of the PPD 
site measurement in millimeters. All pockets measuring 5mm or more were added separately 
to calculate of sum of deep pockets representing diseased sites. The collective sum of PPD 
was further divided by the total number of teeth to provide a tooth adjusted ratio. 
 
∑ 𝑃𝑃𝐷 𝑇𝑜𝑡𝑎𝑙 = 𝑠𝑢𝑚 𝑜𝑓 𝑎𝑙𝑙 𝑝𝑟𝑜𝑏𝑖𝑛𝑔 𝑝𝑜𝑐𝑘𝑒𝑡 𝑑𝑒𝑝𝑡ℎ𝑠 (𝑚𝑚) 
 
∑ 𝑃𝑃𝐷 𝐷𝑖𝑠𝑒𝑎𝑠𝑒 = 𝑠𝑢𝑚 𝑜𝑓 𝑝𝑟𝑜𝑏𝑖𝑛𝑔 𝑝𝑜𝑐𝑘𝑒𝑡 𝑑𝑒𝑝𝑡ℎ𝑠 ≥ 5𝑚𝑚 
                                         
                             Tooth - adjusted PPD Total =   
∑𝑃𝑃𝐷 𝑇𝑜𝑡𝑎𝑙
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑒𝑒𝑡ℎ⁄  
 
 
 
RADIOGRAPHIC EVALUATION 
Radiographic evaluation was performed for studies II, III and IV to quantify marginal bone 
loss (MBL). Panoramic radiographs were taken for all study subjects using a digital extra oral 
tomography machine (SironaOrthophos 3, Germany) at the Department of Periodontology, 
Altamash institute of Dental Medicine, Karachi, Pakistan. All radiographs were measured 
digitally on a computer screen using SIDEXIS software. One pixel was equal to 0.09mm. The 
assessment for MBL was made as a vertical measurement starting from the cementoenamel 
junction (CEJ) and terminating at the most apical portion of the marginal bone. MBL was 
measured for premolars and molars (excluding third molars). An average value for MBL per 
tooth was calculated after taking two readings of mesial and distal sides each on digital 
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radiographs. Teeth at which the CEJ and bone crest were not clear because of technical issues 
such as overlapping restorations or dental caries were excluded.  
 
DAS28 
The DAS28 is a Disease Activity Score based on 28 joints for RA which is used to make a 
reproducible and comparable assessment of the rheumatoid arthritis activity (Prevoo et al., 
1995). DAS28 scoring was used in study III and IV for all RA subjects, calculated by the 
referring rheumatologist. DAS28 scoring is based on the following: number of tender joints, 
number of swollen joints, visual analogue scale score of the patient’s global health, and 
erythrocyte sedimentation rate (ESR).  Remission was considered for a score between 0 and 
<2.6. Low activity corresponded to 2.6 to <3.2 whereas moderate activity was between 3.2 
and ≤ 5.1. High activity was strictly above 5.1.  
 
BLOOD SAMPLE 
Peripheral venous blood via venipuncture was collected from all subjects. The samples were 
collected in 4 ml serum tubes without any additives (Vacutainer tubes, BD Biosciences, 
USA). The blood samples were allowed to coagulate and then centrifuged at 1790 x g for 10 
minutes. Post- centrifugation, the serum was transferred to 2ml storage tubes and were kept 
frozen at -22°C in Pakistan until their transportation to Sweden where they were stored at -
80°C. 
 
 
SEROLOGICAL ANALYSES 
 
IgM RF and ESR 
For study II, III and IV, IgM-RF levels and ESR were measured for all RA patients. For 
quantification of rheumatoid factor (RF), turbidimetric reagents were used in an automated 
clinical chemistry system. The reagent Quantia RF 6K44-01(Abbott Diagnostics, Illinois, 
USA) comprises of R1 (activation buffer) and R2 which is a suspension of polystyrene latex 
particles of uniform size coated with human gamma globulin. The sample was mixed with 
reagent R1 and R2, after which agglutination occurs. This was then measured by turbidimetry 
allowing quantitative determination of IgM-RF using Abbott ARCHITECT c8000 system 
(Abbott Diagnostics). Results are expressed in IU/mL based on the WHO standard (Anderson 
et al., 1970). The system was closely monitored.  Both high and low controls were run with 
every batch analyzed. The within-run CV was 0.6% at concentration 54.8 IU/ml and 0.7% at 
119.9 IU/ml. The levels of RF < 30 U/ml were defined normal, 30 - 50 U/ml as low level 
positive and values > 50 U/ml as high-level positive. ESR was estimated by using the 
Westergren method manually (normal range: 0 to 20 mm per hour). 
 
Anti-cyclic citrullinated peptide (anti-CCP) antibodies 
For study II, anti-CCP antibodies were measured for all subjects. BioPlex®2200 
immunoassay was used to analyze the anti-CCP levels in the serum samples (Bio-Plex™ 
2200 anti-CCP, Bio-Rad Laboratories, Hercules, CA, USA). The principle of this 
immunoassay method is based on the heterogeneous sets of magnetic beads allowing semi-
quantitative detection of IgG antibodies to cyclic citrullinated peptide (CCP) in serum. In this 
system, the patient sample aliquot, sample diluent, and bead reagent are combined into a 
reaction vessel and incubated at 37˚C. After a wash cycle, unbound antibodies are removed 
and anti-human IgG conjugated to phycoerythrin is added to the mixture which is incubated 
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at 37˚C. Excess conjugate is removed in another cycle and the washed beads are re-
suspended on wash buffer. The bead mixture is then passed through the detector and the 
assay identity is determined by the fluorescence embedded in the surface of the bead. The 
amount of immobilized antibody is determined by the fluorescence of the anti-IgG reporter 
conjugate. Raw data are collected in relative fluorescence intensity (RFI). The RFI is 
converted to U/mL using the calibration curve established by the six levels of BioPlex®2200 
Anti-CCP Calibrators. All the samples were run as singletons. 
 
HbA1C 
Glycated hemoglobin levels were determined for all subjects in study IV. Blood was drawn in 
4 ml collection tubes with EDTA (Vacutainer tubes, BD Biosciences, USA). The tubes were 
submitted on the same day for HbA1c analyses at Karachi Laboratory Diagnostic Centre, 
Karachi, Pakistan. For quantification of HbA1c, a Hemoglobin A1c program based on ion-
exchange high-performance liquid chromatography was performed using the Bio-Rad D-10 
Hemoglobin Testing System (Bio-Rad Laboratories, Hercules, CA, USA). 
 
Multiplex PEA-based immunoassay 
The proximity extension assay (PEA) is a homogenous immunoassay which is based on 94 
pairs of specific antibodies that are equipped with oligonucleotides (PEA probes) and mixed 
with an antigen-containing sample.  Upon sample incubation, all proximity probe pairs bind 
their specific antigens, which brings the probe oligonucleotides in close proximity to 
hybridize. The oligonucleotides have unique annealing sites that allows pair-wise binding of 
matching probes. Addition of a DNA polymerase leads to an extension and joining of the two 
oligonucleotides and formation of a PCR template. Universal primers are utilized to pre- 
amplify all 96 different DNA templates in parallel. Uracil-DNA glycosylase partly digests the 
DNA templates and remove all unbound primers. Finally, each individual DNA sequence is 
detected and quantified using specific primers in by microfluidic qPCR. 
Proseek Multiplex Inflammation I (Olink Bioscience, Uppsala, Sweden), was used for 
conducting PEA, according to the manufacturer's instructions. The panel simultaneously 
measures 92 biomarkers, as a homogeneous assay, in a 96-well microtiter plate format. The 
samples were assayed as singletons. One microliter (µl) sample was mixed with 3 μl 
incubation mix that contained pairs of probes (each consisting of a DNA oligonucleotide 
labelled). This mixture was incubated at 8 °C overnight, followed by addition of 96 μl 
extension mix containing PEA enzyme and PCR reagents which were added and incubated 
for 5 min at room temperature before transferring the plate to a thermal cycler. In the cycler, 
the plate underwent 17 cycles of DNA amplification. A 96.96 Dynamic Array IFC (Fluidigm, 
South San Francisco, CA, USA) was prepared and primed according to the manufacturer's 
instructions. Using 7.2 μl detection mix and mixing it with 2.8 μl of sample mixture in a new 
plate, 5 μl of this was loaded into the right side of the primed 96.96 Dynamic Array IFC. On 
the left side of the 96.96 Dynamic Array IFC, the unique primer pairs for each cytokine were 
loaded and the protein expression program was run in Fluidigm Biomark reader, in 
accordance with the instructions. Details regarding data validation, limit of detection (LOD), 
specificity and reproducibility are available via Olink’s website (http://www.olink.com/data-
you-can-trust/validation/). Calibrator curves for correlating the normalized protein expression 
(NPX) values with actual concentrations can also be found in Olink’s website 
(http://www.olink.com/proseek-multiplex/inflammation/biomarkers/). The assays were 
performed blinded without knowledge of clinical data. 
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ELISA  
For study I, 96-well polystyrene plates were used which were coated with 0.25 µg/ well of 
RAP overnight in coating buffer (1.59 g Na2CO3, 2.93 g NaHCO3, 200 mg NaN3) at 4° 
overnight and incubated with medium samples for 1 hr at 4°. Bound LRP1 was detected 
using anti-LRP1 antibody 0.001 µg/ml (1 hr; 4°), rabbit anti-mouse diluted 1:1000 (1 hr; 4°), 
and a sheep anti-rabbit immunoglobulin diluted 1 : 4000 (1 hr; 4°). 
For study III, Human Osteopontin (OPN), TNF R1, TNF R2 and RANKL were analyzed 
using commercial sandwich ELISAs (DY1433, DY225, DY726 and DY626, R&D Systems, 
Minneapolis, MN, USA). The assays utilized a monoclonal antibody which was specific for 
each peptide and coated onto separate microtiter plates.  Standards were assayed as duplicates 
and samples were assayed as singletons. They were pipetted into the wells and the peptides 
were bound to the immobilized antibodies.  After washing, a biotinylated antibody was 
added. After another incubation and washing cycle, a streptavidine-HRP conjugate was added 
to the wells followed by further incubation and washing. This was followed by the addition of 
a substrate solution.  The development was stopped and the absorbance was measured in a 
SpectraMax 250 (Molecular Devices, Sunnyvale, CA, USA). The peptide concentrations in 
the samples were determined by comparing the optical density of the sample with the 
standard curve. The coefficient of variation for the ELISAs were approximately 6%. 
 
QUANTITATIVE IMMUNOCYTOCHEMISTRY 
The expression of cell surface antigens was analyzed in cells fixed in 2% paraformaldehyde 
at 4° attached to glass slides coated with poly-L-lysine (PLL), intercellular adhesion molecule 
1 (ICAM-1) or fibronectin at 4° overnight. Antigen expression was detected with monoclonal 
antibodies and a complex of biotinylated peroxidase and avidin (Vector Laboratories, 
Burlingame, CA). For detection of intracellular antigens cells were fixed in 2% 
paraformaldehyde and permeabilized by 0.1% saponin. The cells were examined in a Nikon 
Eclipse E1000M microscope. The intensity of the immunocytochemical staining was 
quantified using the image processing and analysis program IMAGEJ. 
 
SMALL INTERFERING RNA-MEDIATED GENE SILENCING  
The expression of LRP1 was suppressed using the human T-cell Nucleofector kit (Lonza, 
Köln, Germany) and a Nucleofector device (Amaxa biosystems, Köln, Germany). Briefly, 5 x 
106 T enriched cells were resuspended in 100 µl of nucleofactor solution and transfected with 
500 nM final concentration of small interfering RNA (siRNA) using protocol U14. The 
siRNA consisted of TSP-1 siRNA (human) (Alternative 1) (A:Sense: 
CCACGAUGAUGACAACGAUtt. Antisense: AUCGUUGUCAUCAUCGUGGtt. B: Sense: 
CGAGACGAUUGUAUGAAGAtt. Antisense: UCUUCAUACAAUCGUCUCGtt. C: Sense: 
GAAGAAGCGUAAAGACUAUtt. Antisense: AUAGUCUUUACGCUUCUUCtt), LRP1 
siRNA (Alternative 1) (human). Sense: AAGACUUGCAGCCCCAAGCAGtt. Antisense: 
CUGCUUGGGGCUGCAAGUCUUtt) and control siRNA (sc-37007) from Santa Cruz 
Biotechnology (Dallas, TX) delivered by AH diagnostics, Skärholmen, Sweden. TSP-1 
siRNASuppl (human): (Sense: GCAUGACCCUCGUCACAUAtt. Antisense: 
UAUGUGACGAGGGUCAUGCca) and LRP1 SiRNASuppl (human) (Sense: 
GCUGUGACAUGGACCAGUUtt. Antisense: AACUGGUCCAUGUCACAGCgg) were 
obtained from Applied Biosystems (Stockholm, Sweden). The degree of gene silencing and 
the influence of silencing on adhesion and activation were determined 40 hr after introducing 
siRNAs. 
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BIOTINYLATION AND IMMUNOPRECIPITATION  
The surface membrane of lymphocytes was labelled with D-biotinyl-e-aminocaproic acid-N-
hydroxysuccinimide ester (biotin-7-NHS) according to the manufacturer’s description (Roche 
Diagnostics GmbH, Germany). For immunoprecipitation, adherent cells were first 
biotinylated, released by a cell scraper and then immunoprecipitated. Cells which were in 
suspension and non-adherent cells were biotinylated and immunoprecipitated directly. A 75 
µl stop solution per tube was used to stop the reaction after incubation for 15 min at room 
temperature and centrifuged at 490 g for 10 min. After discarding the supernatant, 5 ml cold 
PBS was added to each tube followed by centrifugation at 490 g for 10 min. Using 1 ml lysis 
buffer (50 mM core buffer, 150 mM NaCl, 0.1 mg/ml PMSF, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin, 1% Nonidet P-40 and 0.5% sodium deoxycholate), the cells were lysed and 
incubated for 30 min on ice. The cells were resuspended after incubation and centrifuged at 
12 000 g for 10 min at 4° after which the supernatants were transferred to clean Eppendorf 
tubes. Immunoprecipitation was carried out with protein G agarose beads according to the 
manufacturer’s instructions (Roche). The supernatants were mixed with 1 µg antibody at 4° 
overnight followed by centrifugation at 12 000 g at 4° for 20 seconds. Subsequently, the 
supernatants were discarded and the beads were re-suspended in 1 ml washing buffer, and 
centrifuged again at 12 000 g at 4° for 20 seconds, the same procedure was repeated twice. 
After washing, 20 µl reducing buffer (2 x, containing 0.15 g dithiothreitol in 5 ml 
immunoprecipitation buffer (150mM NaCl, 10 mM Tris-HCL pH 7.4)) was mixed with the 
beads and heated at 95° for 4 min and subsequently centrifuged at 7000 g for 1 min to spin 
down the beads and the proteins were separated on SDS–PAGE gels. Proteins were 
transferred to the Hybond ECL membrane (Amersham, Chalfont St Giles, UK) and detected 
using the BMC chemiluminescence blotting kit (Roche). 
 
Western blotting 
After separation of the samples on SDS–PAGE gels, they were blotted onto a nitrocellulose 
membrane (Amersham) and blocked over night with PBS, 4% BSA, and 0.5% Tween. Filters 
were washed with PBS with 1.5% BSA and incubated with antibodies. ECL Western blotting 
detection reagents were used for detection with Hyperfilm TM (Amersham). 
 
Cell motility 
Collagen type 1 was first diluted in serum-free RPMI-1640 and H2O (8/1/1) after which it 
was applied in plastic Petri dishes 1 ml/dish (30 mm; BD Biosciences, Franklin Lakes, NJ). It 
was then allowed to polymerize at room temperature. Using AIM-V medium, a total of 1.0 x 
106 cells was added to each well with and without antibodies and allowed to migrate for 
different times. The cells were fixed in 2.5% glutaraldehyde for 10 min or in 2% 
paraformaldehyde for 20 min for immunocytochemistry and washed twice with PBS. Cell 
morphology and cell migration were evaluated in nine fixed positions in each well.  An 
inverted microscope (Nikon Eclipse TE300) and a digital depth meter (Heidenheim ND221) 
were used to study cell morphology and migration at 50-µm intervals throughout the gel. The 
mean number of infiltrating cells/field (x 20 objective) per infiltration depth (50 µm for the 
first two layers immediately beneath the gel surface and 100 µm for other layers further 
down) were recorded as results. After fixation in paraformaldehyde, immunocytochemistry 
was used to identify the infiltrating cells in situ in the collagen gels. Migration was also 
analysed in a modified Boyden assay (transwell assay) using 8-µm nucleopore filters coated 
with ICAM-1 (2 µg/ml) or fibronectin (10 µg/ml). The lower wells of 48-well Boyden 
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chambers were filled with RPMI containing 1 mg/ml BSA and CXCL12 (50 ng/ml) 
whereupon the coated filters were placed in the chambers. The upper chambers were filled 
with 50 µl of 2 x 106 cells/ml in AIM-V. Following incubation for 1 hr, the number of cells in 
the lower chamber was counted in triplicate. 
 
Cell adhesion 
In order to study cell adhesion, plastic Petri dishes (90 mm; Heger A/S, Rjukan, Norway) 
were coated with ICAM-1 (2 µg/ml), poly-L-lysine (10 µg/ml) or fibronectin (10 µg/ ml), and 
extensively washed before use. Using AIM-V medium, the cells (10 000/position) were 
incubated on the substrates for different times, then fixed in 2.4% cold glutaraldehyde for 10 
min for immunocytochemistry and unbound cells were removed by gentle aspiration. The 
number of adherent cells per microscope field (20 x objective) was counted. 
 
T-cell activation 
T cell activation was achieved using mixed lymphocyte culture activation. T cells were co-
cultured with inactivated allogeneic stimulator cells whereupon interferon-c (IFN-c) and 
interleukin-2 (IL-2) production was determined by an ELISPOT assay. T-cell activation was 
also accomplished using anti-CD3. T cells were cultured on a surface coated with anti-CD3 
antibodies with and without CXCL12. 
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STATISTICAL ANALYSES 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) 
version 21.0 (SPSS Inc, Chicago, IL, USA). The significance level was set at 5%. 
 
In study I, parametric tests were used as staining intensity in immunocytochemistry 
experiments, number of migrating cells and adherent cells were presented as mean ± SD in 
arbitrary units. For evaluating differences between groups, the Mann–Whitney U test was 
used. For determination of differences in migration assays, paired Student’s t-test was used.  
 
In study II, parametric tests were used to calculate the differences in periodontal parameters 
between the study groups. One-way ANOVA was used for this comparison. Tukey's HSD 
(honest significant difference) test was used in conjunction with one-way ANOVA to correct 
for family-wise error rate that can occur during multiple comparisons. For biomarker 
analyses, the data was normalized and generated as Normalized Protein eXpression (NPX) 
unit on a log2 scale and reported in NPX units. A larger NPX number represents a higher 
protein level in the sample, with the background level at around zero. This was done using a 
Wizard generated by Olink, together with the statistical software GenEx. The assay generated 
a delta Cq (dcq) value for each data point via Olink Wizard with GenEx software thus 
normalizing each sample for technical variation in one run. This was followed by 
normalization between runs through subtraction of the interplate control (IPC) for each assay. 
For the final step, the values were set relative to a fixed correction factor which is determined 
by Olink. Non-parametric Spearman's rank correlation was performed to analyze the 
associations between cytokine levels and clinical parameters, respectively. To reduce the risk 
of false discoveries due to multiple testing, the Benjamini-Hochberg false discovery rate 
method was used to adjust the p-values.  
 
For study III, non-parametric statistics were used as data are reported as medians and 
interquartile ranges. Group wise comparison for analyzing the variables was performed using 
the Mann–Whitney U test. Spearman rho coefficient was used to correlate between markers 
in the study groups and clinical parameters. To reduce the risk of false discoveries, the 
Benjamini-Hochberg false discovery rate method was used for adjusting values.  
 
In study IV, data are reported as medians and interquartile ranges. For group wise 
comparison, the Mann–Whitney U  test was used. Spearman rho coefficient was used to 
correlate between variables in the study groups. 
 
In studies II, III and IV, all analyses involving MBL were performed using data for 
mandibular MBL as a high proportion of MBL measurements in maxillary premolars and 
molars were not possible. This was due to difficulty in determining the alveolar bone crest.
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RESULTS 
 
STUDY I 
As part of maintaining important immunological patrolling and immuno-surveillance 
functions, T cells require the ability to be motile, adhesive, and activated upon signaling.  We 
wanted to demonstrate whether these characteristics may depend on the large transmembrane 
cell surface receptor low-density lipoprotein receptor-related protein 1 (LRP1) and its ligand 
thrombospondin-1 (TSP-1). LRP1 consists of and α-chain (515 kDa) containing ligand-
binding domains, a β-chain (85 kDa) containing the transmembrane domain and the 
cytoplasmic tail, and has binding sites for more than 40 ligands. TSP1 is a 450-kDa 
glycoprotein composed of three identical disulfide-linked polypeptide chains that display 
binding sites for various cell surface receptors. LRP1 mediates the endocytosis of a vast array 
of distinct ligands, including proteases, protease inhibitor complexes, extracellular matrix 
proteins and growth factors. It also regulates the cell surface abundance of other membrane 
proteins, thereby regulating cell signaling activity (Strickland et al., 2002). We found that co-
stimulation through CD28, integrins such as ICAM -1 and fibronectin, and CXCR4 inhibits a 
protease mechanism that removes LRP1 from the cell surface. This removal or ‘shedding’ of 
LRP1 antagonizes TCR-induced activation. 
 
A broad spectrum metalloprotease inhibitor stimulates cell surface expression 
of LRP1 and TSP-1 expression 
Adhesion experiments in the presence of broad spectrum MMP inhibitor GM6001 showed 
that cells attached on ICAM-1 and fibronectin had pronounced surface expression of LRP1 
and TSP-1 (P < 0.01) compared to those without. This increase was seen in both non-
stimulated and activated cells. Contact with fibronectin and ICAM-1 also enhanced LRP1 
expression, although not as strongly as in the presence of GM6001. ). The shedding of LRP1 
is brought about by sheddases including ADAM10 (Shackleton et al., 2016). Sheddases are 
active proteases from the ADAM (a disintegrin and metalloproteinase) membrane-bound 
enzymes that cleave extracellular portions of proteins from the cell surface. ADAM10 is a 
sheddase that might be responsible for the shedding of LRP1 in non-lymphoid cells, and 
represent a general shedding machinery for membrane proteins. LRP1 was detectable in the 
culture medium of T cells and that GM6001 (10 µM) and the ADAM10 inhibitor GI254023X 
(5 µM) reduced the appearance of LRP1 in the medium. 
Comparison of the cell surface expression of TSP-1 induced by adhesion with the total 
cellular TSP-1 before adhesion using Western blotting showed that T cells before adhesion 
exhibited negligible surface expression of TSP-1. Adhesion to ICAM-1, triggered surface 
expression of 170 000 and 130 000 bands precipitated with an antibody to TSP-1. In cells 
incubated in the presence of GM6001, anti-TSP-1 precipitated a 170 000 (full length TSP-1) 
band and an almost negligible 500 000 band (LRP1). In cells on ICAM-1, anti-LRP1 
precipitated a prominent 500 000 band and relatively weak 170 000 and 130 000 bands. In 
cells incubated on ICAM-1 in the presence of GM6001, anti-LRP1 precipitated a very 
prominent 500 000 band and prominent 170 000 and 130 000 bands, whereas anti-TSP-1 
precipitated very prominent 170 000 and 130 000 bands and a prominent 500 000 band. 
Western blotting of cells incubated on ICAM-1 in the presence of GM6001 confirmed that 
the 500 000 band is LRP1 and that the 170 000 and 130 000 bands are TSP-1. This Western 
blot also confirmed that anti-LRP1 co-precipitated TSP170 and TSP130, whereas anti-TSP-1 
co-precipitated LRP1.  
 26 
 
 
The reactivity of the anti-LRP1 and anti-TSP-1 antibodies also verified that the presence of 
GM6001 preferentially stimulates LRP1 expression, whereas ICAM-1 stimulates both LRP1 
and TSP-1 expression. 
 
Co-stimulation enhances surface expression of LRP1 
T cells were incubated in the presence of exogenous TSP-1 to see their effect on LRP1 
expression. This TSP-1, but not IgG, was indeed found to prevent shedding of LRP1. We 
next examined whether the enhancing effect of ligation of CD28 (anti-mouse IgG, 2 µg/ml + 
anti-CD28, 50 ng/ml) on LRP1 expression was dependent on shedding. This experiment 
showed that CD28 ligation inhibited the appearance of LRP1 in the medium and increased 
cell surface LRP1. 
 
TSP-1 mediates LRP1-dependent adhesion to ICAM-1 and fibronectin 
To elucidate whether the stimulation of T-cell adhesion to fibronectin and ICAM-1 in the 
presence of GM6001 and GI252023X was dependent on LRP1 and/ or TSP-1, siRNA was 
used to silence these molecules. The siRNA results showed that LRP1 siRNA as well as TSP-
1 siRNA markedly reduced TCR-induced T-cell activation. LRP1 siRNA increased the cell 
surface expression of TSP-1. This indicates that an increased cell surface expression of TSP-1 
accounts for the enhancement of adhesion by LRP1 siRNA. 
 
GM6001 and CXCL12 enhance TCR-induced T-cell activation through TSP-1 
and LRP1 
By examining the influence of knockdown of TSP-1 and LRP1 on T-cell activation by anti- 
CD3 (50 ng/ml) in the presence of CXCL12, we observed that TSP-1 siRNA inhibited anti-
CD3-induced IFN-c production as well as the enhancing effect of CXCL12. Control siRNA 
did not inhibit IFN-c production. LRP1 siRNA had a relatively weak albeit significant 
inhibitory effect whereas a combination of TSP-1 siRNA and LRP siRNA had a pronounced 
inhibitory effect. 
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STUDY II 
 
Characteristics of Study Subjects 
The characteristics of all the study subjects are presented in Tables 5a. 
 Table 5a.  Characteristics of Study Group 
RA=rheumatoid arthritis PD= periodontal disease. 
 
 
 
 
The characteristics for the RA groups (with and without PD) are presented in table 5b. On 
comparison, the IgM-RF levels were higher in the RA with PD group. All remaining 
rheumatological characteristics were comparable between the two groups. 
 
Table 5b. Characteristics of the rheumatoid arthritis (RA) group 
Values are shown as mean ± SD.  
IU = international units 
Anti-CCP values are expressed as arbitrary units (U/ml) 
PD= periodontal disease 
 
 
 
 
 
 
 
  
Total subjects (n) 90 
Mean age distribution in years (range) 46.4 ± 10.1 (21 – 70) 
Females (n, %) 64 (71) 
Total subjects with RA (n) 38 
Subjects with RA and PD (n, %) 19 (50) 
Subjects with RA and without PD (n, %) 19 (50) 
Total subjects with PD only (n) 38 
Healthy Controls (n) 14 
Characteristic RA without PD 
(n=19) 
RA with PD 
(n=19) 
P-value 
Years since diagnosis 8.7 8.1 0.76 
IgM-RF (≥30 IU/mL) 117.5 168.7 0.04 
ESR (mm/hr) 49.8 54.8 0.15 
Anti-CCP (≥ 3 U/mL) 251.7 286.1 0.62 
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Biomarkers 
 
The inclusion of biomarkers for analytical purpose was based on the criteria that ≥ 60% of 
subjects should have detectable levels for the given biomarker. According to this criteria, a 
total of 66 cytokines qualified out of 92 which are shown in Table 6. 
 
 
Table 6. Biomarkers with ≥ 60% of results included in the analyses  
 
 
*Common synonyms used in Olink inflammation Panel (Panezai et al., 2017). 
 
 
 
 
Adenosine Deaminase (ADA)  Interleukin-10 receptor subunit alpha (IL-10RA)  
Beta-nerve growth factor (Beta-NGF) Interleukin-10 receptor subunit beta (IL-10RB)  
Caspase 8 (CASP-8 )  Interleukin-12 subunit beta (IL-12B)  
C-C motif chemokine 2 (CCL2) “MCP-1”* Interleukin-15 receptor subunit alpha (IL-15RA)  
C-C motif chemokine 3 (CCL3) “ MIP-1 alpha” Interleukin-18 (IL-18)  
C-C motif chemokine 4 (CCL4)  Interleukin-18 receptor 1 (IL-18R1) 
C-C motif chemokine 7 (CCL7) “MCP-3” Latency-associated peptide transforming growth 
factor beta 1 (LAP TGF-beta-1) 
C-C motif chemokine 8 (CCL8) “MCP-2” Leukemia inhibitory factor receptor (LIF-R)  
C-C motif chemokine 11 (CCL11) “Eotaxin” Macrophage colony-stimulating factor 1 
 (CSF-1)  
C-C motif chemokine 13 (CCL13) “MCP-4” Matrix metalloproteinase-1 (MMP-1)  
C-C motif chemokine 19 (CCL19)  Matrix metalloproteinase-10 (MMP-10)  
C-C motif chemokine 20 (CCL20)  Natural killer cell receptor 2B4 (CD244)  
C-C motif chemokine 23 (CCL23)  Neurotrophin-3 (NT-3)  
C-C motif chemokine 25 (CCL25)  Oncostatin-M (OSM)  
C-C motif chemokine 28 (CCL28)  Osteoprotegerin (OPG)  
CD40L receptor (CD40)  Programmed cell death 1 ligand 1 (PD-L1)  
CUB domain-containing protein 1 (CDCP1)  Protein S100-A12 (EN-RAGE )  
C-X-C motif chemokine 1 (CXCL1)  Signaling lymphocytic activation molecule (SLAMF1)  
C-X-C motif chemokine 5 (CXCL5)  SIR2-like protein 2 (SIRT2)  
C-X-C motif chemokine 6 (CXCL6)  STAM-binding protein (STAMPB)  
C-X-C motif chemokine 8 (CXCL8) “IL-8” Stem cell factor (SCF)  
C-X-C motif chemokine 9 (CXCL9 )  Sulfotransferase 1A1 (ST1A1)  
C-X-C motif chemokine 10 (CXCL10)  T-cell surface glycoprotein CD5 (CD5)  
C-X-C motif chemokine 11 (CXCL11)  T cell surface glycoprotein CD6 isoform (CD6)  
C-X3-C  motif chemokine ligand 1(CX3CL1)  
 “ Fractalkine” 
TNF-beta (TNFB)  
Cystatin D (CST5)  TNF-related activation-induced cytokine (TRANCE)  
Delta and Notch-like epidermal growth factor-related 
receptor (DNER)  
TNF-related apoptosis-inducing ligand (TRAIL)  
Fibroblast growth factor 19 (FGF-19) Transforming growth factor alpha (TGF-alpha)  
Fms-related tyrosine kinase 3 ligand (Flt3L)  Tumor necrosis factor (Ligand) superfamily, member 
12 (TWEAK)  
Hepatocyte growth factor (HGF) Tumor necrosis factor ligand superfamily member 
14 (TNFSF14)  
Interleukin-6 (IL-6)  Tumor necrosis factor receptor superfamily member 
9 (TNFRSF9)  
Interleukin-7 (IL-7)  Urokinase-type plasminogen activator (uPA)  
Interleukin-10 (IL-10)  Vascular endothelial growth factor A (VEGF-A)  
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Periodontal Parameters for study groups.  
Results for comparison of periodontal parameters between healthy, RA (with and without 
PD) and PD groups are shown in Table 7. The number of pockets measuring 3- <5mm did 
not differ between the PD and RA disease groups. Mean values for MBL, BOP and 
PPD≥5mm were the highest in the PD group. The number of teeth were comparable 
between all four groups. 
 
Table 7. Clinical (BOP, PPD 3-<5mm, PPD ≥5mm, number of teeth) and radiographic 
(mandibular MBL) parameters in RA (with and without PD), PD and healthy groups 
 
Differences in the means ± SD of clinical parameters were tested using one-way ANOVA. For multiple comparisons, 
post- hoc Tukey HSD test was performed.   
* compared to RA without PD. P<0.01  
‡ compared RA with PD. P<0.01   
§ compared to healthy controls. P<0.01  
** compared to healthy controls. P<0.05   
BOP = Bleeding on probing, PPD= Probing pocket depth, MBL= marginal bone loss   
RA=rheumatoid arthritis PD= periodontal disease 
 
Correlation of cytokines with periodontal parameters 
All correlations determined between five periodontal parameters and 66 different cytokines 
(66 × 5) are shown in Figure 6. The periodontal parameters comprised of shallow (measuring 
3-<5mm) and deep (measuring ≥ 5mm) pockets, BOP, mandibular MBL and number of teeth 
which were used to identify associations with cytokine levels using Spearman rank. RA 
subjects with PD were excluded in order to avoid positive or negative confounding and the 
analyses was conducted for a singular cohort of 69 subjects. All cytokines were found to 
correlate negatively with the number of shallow pockets except for CD40. For BOP, five 
cytokines were positively correlated, while the remaining five were inversely correlated. The 
number of deep pockets was significantly correlated with a total of 18 cytokines out of which 
eight were positively and ten were inversely correlated. A total of seventeen cytokines 
correlated significantly with MBL. A higher frequency of significant correlations was seen 
for number of teeth which associated with 27 cytokines out of which only five were negative 
coefficients. 
 
 
 
 
 
 
 
 
PD 
(n=38) 
RA  with PD 
(n= 19) 
RA without PD 
(n= 19) 
Healthy 
(n=14) 
BOP% 76.2 ± 27*‡§ 37 ± 32 42.6 ± 31‡ 
 
27.2 ± 29.4 
PPD 3- <5mm 49.2 ± 17.4§ 43.5 ± 17.9** 55.5 ± 16.2§ 
 
26.9 ± 14.1* 
PPD≥ 5mm 33.4 ± 14.1*‡§ 18.2 ± 15.2§ 0.32 ± 0.74‡ 
 
0.4 ± 0.5 
Number of  Teeth 
 
24.8 ± 4.3 
 
25.5 ± 4.1 26.8 ± 2.9 26.1 ± 4.7 
Mandibular MBL mm 5.4 ± 2.6*‡§ 3.8 ± 2.2 2.9 ± 1 
 
 
3.3 ± 0.7 
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Figure 6. Heatmap showing Spearman correlation between clinical parameters and 66 
different cytokines (66 × 5) for a singular cohort of 69 subjects.  
*P < 0.05 
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Subgroup analysis for correlation of cytokines in RA subjects 
In order to compare which cytokines correlated with periodontal variables under the influence 
of periodontal disease, a subgroup analysis was performed for RA subjects. Results for 
significant correlations are shown in Figures 7 and 8. In RA without PD subjects, MBL was 
found to correlate positively with SLAMF1, CST5 and ADA whereas number of teeth were 
correlated with DNER. Shallow pockets (PPD 3-<5mm) were found to inversely correlate 
with MMP-10 and TGFA whereas BOP with ADA and SLAMF1 respectively. 
In RA with PD subjects, Flt3L and EN-RAGE with BOP and MCP-3 with MBL were the 
only two markers to correlate positively.  
 
 
 
 
 
 
 
 
 
Figure 7. Spearman rank correlations between cytokines and clinical parameters for 
RA group without PD (n=19). The x axis represents Spearman r coefficient. All correlations 
shown are significant (P < 0.05). 
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Figure 8. Spearman rank correlations between cytokines and clinical parameters for  
 RA group with PD (n=19). The x axis represents Spearman r coefficient. All correlations 
shown are significant (P < 0.05). 
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STUDY III 
 
 
General characteristics for all study subjects 
A total of 90 subjects participated in this study. The mean age was 46.4 years. The total 
number of subjects diagnosed with PD was 57 (with RA = 19, without RA= 38) while those 
without PD were 33 (with RA = 19, healthy = 14). For comparative analyses, the subjects 
were further divided into four groups: subjects with PD only, RA subjects with and without 
PD and healthy groups. 
 
Correlation between clinical and serological data 
Serum RANKL was found to associate with number of PPD≥5mm (r=0.28, P=0.01) and 
MBL (r = 0.29. P=0.008). Inverse correlations were found between OPN and the number of 
PPD 3-<5mm (r = -0.31, P=0.03) as well as TNFR1 and PPD ≥ 5mm (r=-0.32, P=0.003). 
Results are presented in Figure 9. A further group-wise analysis was also done to observe the 
effects of PD on correlations between serum analytes and clinical parameters. The highest 
number of correlations were seen in the RA with PD group in which RANKL (r= -0.46), 
OPN (r=-0.62) and TNFR1 (r = -0.51) correlated negatively with BOP. Levels of RANKL 
(r= -0.5), OPN (r = -0.57) and TNFR1 (r = -0.62) also correlated negatively with number of 
shallow pockets (PPD 3-<5mm) in this group. In the PD group, an inverse correlation was 
seen for TNFR1 with MBL (r = -0.45).  
 
Serum levels of OPN, RANKL, TNFR1, TNFR2, OPG and RANKL/OPG ratio 
Comparison of serum concentrations between the four groups for OPN, RANKL, TNFR1, 
TNFR2 OPG levels and RANKL/ OPG ratio are shown in Table 8. RA with PD subjects had 
the highest medians for OPN, RANKL, TNFR2 and OPG. RA without PD subjects and the 
PD group had comparable levels for all four markers. RANKL levels were comparable 
between the RA (with and without PD) and PD groups. All markers were increased in RA 
subjects suffering from PD as compared to those without. There was no difference between 
the PD and RA without PD group. The analyses for RANKL/OPG ratio revealed that the 
ratios were comparable between PD and RA groups, however the ratio differed between the 
RA groups, with higher levels prevailing in those without PD. The PD and both RA groups 
had increased ratios in comparison to healthy subjects. 
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Figure 9. Correlations between clinical and serological data for all study subjects  
(n =90). The x axis represents Spearman r coefficient. 
* Adjusted P-value < 0.05 
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Table 8. Serum levels of OPN, RANKL, TNFR1, TNFR2, OPG and RANKL/OPG ratio 
in RA (with and without PD), PD and healthy groups 
 
 
a compared to RA without PD. P<0.05 
b compared to RA without PD. P<0.01  
c compared RA with PD. P<0.05   
d compared to healthy controls. P<0.05 
e compared to healthy controls. P<0.01   
f compared to healthy controls. P<0.001   
All values are shown as median ± IQR 
 au = arbitrary units 
 
 
 
Correlation between analytes 
Pairwise correlation between analytes was done for all four study groups. The number of 
significant correlations was most frequently observed in the RA with PD group where 
RANKL correlated with OPN (r = 0.55) and TNFR1 (r = 0.50), OPN with TNFR1 (r = 0.75) 
and TNR1 with TNFR2 (r = 0.52). In RA subjects without PD, TNFR1 correlated with 
RANKL (r=0.63), OPN (r = 0.50) and TNFR2 (r = 0.49). In PD subjects, TNFR1 correlated 
with OPN (r = 0.46) and TNFR2 (r = 0.58). TNFR1 and R2 also correlated significantly in 
the healthy group (r = 0.54). 
 
 
 
  
 
PD 
(n=38) 
RA with PD 
(n=19) 
RA without PD 
(n=19) 
H 
(n=14) 
OPN (pg/ml) 1332 ± 1135 
c f
 4021.7± 5393.5
b
 1202.2 ± 874.6 3454 ± 1764.5
b
 
RANKL (pg/ml) 
 
224 ± 117.2 
f
 
 
242 ± 116 
b f 
 
 
183.5 ± 69 
d
 
 
70 ± 113.5 
TNFR1 (pg/m) 266.6 ± 618.2 
c e
 931.4 ± 1007 
b e
 141.2 ± 451 963.5 ± 745 
TNFR2 (pg/ml) 4113 ± 1731.2 
c d
 
4836 ± 3270.4 
b 
e
 
3938 ± 1975.5 3320 ± 2056 
OPG (au) 10.06 ± 0.52 
c d
 10.34 ± 0.49 
b f
 10.15 ± 0.55 9.82 ± 0.25 
RANKL/OPG (au) 0.77± 0.07 
e
 0.72 ± 0.07 
b d
 0.78 ± 0.06 
e
 0.64 ± 0.1 
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STUDY IV 
In this study, we measured PD severity using a continuous index of PPD Total and PPD 
Disease in subjects with and without rheumatoid arthritis. We also analysed glycated 
hemoglobin levels. 
 
General characteristics for all study subjects 
The total number of participating subjects was 118. Forty-seven subjects were with 
established RA disease. The total number of subjects suffering from periodontal disease was 
77 (with RA = 26, without RA= 51). Healthy controls comprised of 20 persons.  
 
 
 ΣPPD Total, Tooth adjusted ΣPPD Total, MBL and HbA1c levels in study 
groups 
Results for comparison between the four groups for the ΣPPD Total index and tooth adjusted 
ΣPPD Total are shown in Table 9. For both the indices, the medians for the PD group differed 
significantly from the remaining three groups as the group showed the highest values, 
followed by RA with PD and RA without PD. All groups differed from the healthy controls. 
There was no statistical difference between the RA groups for ΣPPD Total but after tooth 
adjustment, the difference was significant. For subjects suffering from PD (PD=51 and RA 
with PD = 26), ΣPPD Disease was more severe in subjects with PD only. Increased MBL was 
seen for the PD group with the highest median as compared to the remaining groups. MBL 
levels were comparable between RA without PD and healthy controls. The serum levels of 
HbA1c were the highest in PD group which differed significantly from RA with PD and 
healthy groups. However, HbA1c levels were comparable between PD and RA without PD 
subjects. Both the RA groups as well as PD had significantly higher HbA1c levels in 
comparison to healthy subjects. 
 
Correlation of glycated hemoglobin with ΣPPD Total, ΣPPD Disease and MBL 
Glycated hemoglobin levels were found to correlate with ΣPPD Total (r = 0.36, P < 0.0001) 
for all subjects (n=118). For subjects with PD (n=77), a correlation analysis between HbA1c 
and ΣPPD Disease also showed a significant correlation (r = 0.25, P<0.05). A significant 
association was also found between glycated hemoglobin levels and MBL for all 118 subjects 
(r = 0.25, P<0.01). The correlation was not significant between HbA1c and MBL in subjects 
with PD (r = 0.21, P = 0.07). 
 
Correlation of Tooth adjusted ΣPPD Total with periodontal parameters  
The correlation analyses between tooth adjusted ΣPPD Total and periodontal parameters 
showed a direct correlation with PPD≥5mm (r= 0.54, P<0.000001) and MBL (r = 0.48, P< 
0.0001). BOP (r = - 0.26, P < 0.05) and ΣPPD Disease (r = - 0.27, P < 0.05) correlated 
showed an inverse relationship between numbers of teeth and inflammatory state. No 
correlation was seen for shallow pockets.  
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Table 9. ΣPPD Total, Tooth adjusted ΣPPD Total, MBL and HbA1c in RA (with and 
without PD), PD and healthy groups 
 
 
a compared to RA without PD. P<0.05 
b compared to RA without PD. P<0.001 
c compared to RA with PD. P < 0.05 
d compared to RA with PD. P<0.01   
e compared to RA with PD. P<0.001 
 f compared to healthy controls. P<0.05 
g compared to healthy controls. P<0.001 
All values are shown as median ± IQR 
NA = not applicable 
 
 
 
Correlation of ΣPPD Disease and ΣPPD Total with number of deep pockets and 
MBL 
To assess the sensitivity of ΣPPD disease, a correlation analyses was done with number of 
PPD ≥ 5mm and MBL for subjects suffering from PD (n = 77). The results showed a strong 
correlation with PPD ≥ 5mm (r = 0.83, P<0.0001) whereas for MBL the correlation was (r = 
0.28, P<0.05). ΣPPD Total correlated strongly as well with PPD≥ 5mm (r = 0.72, P < 0.0001) 
but not with MBL (r = 0.13, P = 0.25). 
 
 
DAS 28 correlation with HbA1c, rheumatological and periodontal parameters 
in RA subjects with and without PD 
In order to assess the degree of correlation between RA disease activity using DAS28 and 
parameters of rheumatologic (IgM-RF, ESR) and periodontal interest (BOP, ΣPPD Total, 
ΣPPD Disease, MBL PPD 3-<5mm, PPD≥5mm) as well as glycated hemoglobin levels and 
age, correlation analyses was carried out. The results showed only three significant 
correlations. An inverse correlation was found between DAS28 and PPD 3-<5mm (r = -0.68, 
P<0.001) in RA with PD subjects.  DAS28 was directly associated with IgM-RF levels in 
both the RA groups with PD (r = 0.39, P<0.05) and without PD (r = 0.47, P < 0.05).  
 
 
 
 
 
 
PD 
(n=51) 
RA with PD 
(n=26) 
RA without PD 
(n=21) 
H 
(n=20) 
ΣPPD Total / mm 384 ± 99 b e g 301 ± 73 g 276 ± 74 g 191 ± 21.5 
Tooth adjusted ΣPPD Total 
 
15.5 ± 3.8 
b e g
 
 
11.7 ± 2.9 
a g
 
 
10.8 ± 2.5 
g
 
 
6.8 ± 0.9 
ΣPPD Disease / mm 229 ± 135 e 108 ± 96 NA NA 
MBL / mm 5.24 ± 2.01 
b c g  4.57 ± 0.9  b g 3.02 ± 0.9 2.92 ± 0.7 
HbA1c (%) 5.7± 1.2 
d g
 5.2 ± 1 
f
 5.4 ± 1.8 
g
 4.4 ± 0.7 
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DISCUSSION 
 
STUDY I 
The results from study I show that low LRP1 expression on T lymphocytes is due to 
continuous shedding (Figure 10).  This LRP1 shedding is spontaneous in nature rather than 
induced by exogenous stimuli which makes it unique (Gorovoy et al. 2010). T cells are 
known to express ADAM10 (Ebsen et al., 2013). 
 
 
Figure 10. Mechanisms underlying T cell regulation through LRP1. (A) T cell membrane 
receptors in contact with integrin ligands and CXCL12 induces cell surface expression of TSP-1 
which in turn inhibits shedding of LRP1. (B) CD28 ligation inhibits shedding of LRP1. 
 
Using a broad spectrum metalloprotease (MMP) inhibitor GM6001, we were able to 
demonstrate the profound effect of this protease inhibitor on LRP1 expression on T cells. 
This indicates that LRP1 is transported to the cell surface and then released by an enzymatic 
mechanism. TSP-1 is one of the many ligands that binds to LRP1. We showed in our study 
that TSP-1 associates heavily with LRP1 once TSP-1 transport to the cell surface has been 
stimulated by cell contact with β1 and β2 integrin ligands. 
 
The preformed TSP fragments TSP170 and TSP130 may be responsible for inhibiting the 
sheddase, thus upregulating LRP1. TSP130 was exclusively expressed in adherent cells 
indicating its pro-adhesive property. Our results suggest that preformed TSP fragments via 
association with LRP1 determine the behavior of T cells with respect to adhesive interaction 
with extracellular matrix, antigen-presenting cells or endothelial cells. 
 
For efficient T-cell activation, both the recognition of antigen by TCR as well as engagement 
of costimulatory molecules are vital. CD28 is widely recognized as the major costimulatory 
protein for naive T-cell activation, and the CD28/B7 pathway plays a central role in immune 
responses (Bour-Jordan et al., 2002). Our findings show that CD28 ligation also inhibits 
shedding of LRP1, although independent of TSP-1. Hence, it is very likely that co-
stimulation may upregulate cell signaling through upregulated T cell expression of LRP1 and 
TSP-1. The LRP1 shedding is a regulatory mechanism directed towards immunosuppression 
and the antagonistic co-stimulatory pathways may have evolved to combine defense against 
pathogens with protection against excessive and adverse immune responses.  
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STUDY II 
In study II we analysed 92 human proteins related to immuno-inflammatory processes in RA 
and PD subjects. We found significant correlations between several proteins and periodontal 
parameters. Our findings reported the association for three novel markers with disease 
severity consistently. FGF-19, ST1A1 and NT3 correlated positively whereas EN-RAGE, 
DNER, TWEAK and CX3CL1 correlated negatively with BOP, PPD>5mm and MBL. There 
are no previous studies on the association of FGF-19, ST1A1 and NT3 with either PD or RA. 
EN-RAGE, DNER, TWEAK and CX3CL1 are proteins abundantly expressed by leucocytes 
as well as neuronal cells (DNER) which, collectively, are either recruiters or stimulators of 
other key mediators of inflammation. The negative correlation between the serological levels 
of these markers and periodontal parameters may be due to their increased engagement and/ 
or consumption at tissue receptor sites undergoing active inflammation.  
 
We also found significant correlation between antigen specific receptor complex associated 
proteins CD5 and CD6.  They are found on TCR and BCR and participate in the modulation 
of signals that allow activation and /or differentiation of T or B cells, depending on the 
signals received from the antigen-receptor complex. A recent study by Orta-Mascaró et al. 
found that CD6 modulates the threshold for thymocyte selection of T cells as well as the 
generation and/or function of several peripheral T cell subpopulations (Orta-Mascaró et al., 
2016). Low levels of CD5 have been found in the serum of healthy individuals, with 
increasing levels reported in some autoimmune diseases such as RA (Jamin et al.,1992) and 
primary Sjögren's syndrome (Ramos-Casals et al.,2001). Soluble CD5 has been shown to 
function as a negative regulator of T and B cell responses resulting in enhanced activation of 
effector T and B cells. The direct association of CD5 and CD6 levels with periodontal 
parameters indicates an anomalous T cell response in PD.  
 
Further analysis also revealed an inverse correlation for both IL-10 and its receptors with 
periodontal parameters (PPD 3-<5mm, MBL). This was also observed in RA with PD 
subjects (BOP, PPD 3-<5mm and ≥5mm). This inverse correlation mirrors a compromised 
regulatory mechanism which allows to sustain inflammation. IL-10 is anti-inflammatory 
known to potently inhibit TNF-α production along with other pro-inflammatory cytokines, 
including IL-1 and IL-6 (Moore et al., 2001, Brennan et al., 2008). For the exception of 
CCL25, most chemokines associated inversely with clinical parameters. This may be 
explained in part by the RA group receiving strong anti-inflammatory medication (NSAIDS, 
corticosteroids, DMARDs) which can exert an inhibitory effect on chemokine production 
(Szekanecz et al., 2010).  
 
Apoptosis associated proteins were also found to be associated with disease severity. CASP-8 
with BOP and PPD ≥5mm, HGF with PPD ≥5mm, and CDCP1 with MBL indicate that 
inflammatory and apoptotic processes may be interlinked in PD. There is evidence for the 
role of CASP-8 in leading osteoblasts to early programmed cell death via prior sensitization 
to apoptotic signals (Mori et al, 2009). HGF levels in GCF and saliva have been shown to 
increase proportionally with the severity of PD (Nagaraja & Pradeep, 2007). HGF is also an 
osteoclast secreted clastokine with a role in inducing osteopontin production by osteoblasts 
(Chen et al., 2012). 
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STUDY III 
In study III, we investigated concentrations of OPN, RANKL, TNFR1, TNFR2, OPG and the 
RANKL/OPG ratio in serum samples from subjects suffering from periodontal disease alone, 
suffering from rheumatoid arthritis with and without periodontal disease and healthy groups. 
 
Osteopontin (OPN) is a phosphoprotein mainly secreted extracellularly. It can regulate 
mineral crystal growth as well as mediate cell attachment and signaling via recognition of 
integrins (Sodek et al., 2013). OPN is recognized as a matricellular protein as well as a 
cytokine involved in the recruitment of immune cells in inflammation (Merry et al., 1993, 
Rittling et al., 1998). Our results showed differences in OPN levels between the PD and RA 
subjects suffering from PD. This may be explained by the fact that soluble OPN is released 
by both osteoblasts and osteoclasts which may negatively regulate osteoclast precursor 
formation as part of a negative feedback mechanism (Giachelli et al., 2000). This mechanism 
may be a compensatory response in an attempt to maintain bone levels in osteolytic diseases, 
as reflected by higher serum levels of OPN seen in RA with PD subjects. 
 
Serum levels of RANKL in PD subjects were comparable to both the RA groups which 
shows an extensive involvement of immune cells in PD. This is a highly notable finding 
given that osteolysis in RA involves multiple sites as compared to alveolar bone loss of the 
jaws in PD. Higher RANKL levels were also associated positively with two clinical 
parameters of disease severity, PPD ≥5mm and MBL. This finding supports that of a recent 
study in which RANKL serum levels were also associated with PPD (Baltacıoğlu et al., 
2014). Besides serum, RANKL concentration levels in periodontal tissues have been shown 
to correlate with increasing pocket depth (Kawai et al., 2006). Elevation of RANKL has also 
been observed in gingival crevicular fluid (GCF) in PD patients (Bostanci et al., 2007). The 
cellular sources of RANKL include osteoblasts, dendritic cells, periodontal ligament 
fibroblasts but mostly B and T cells (Bertl et al., 2012). For bone destruction to take place, a 
certain critical level of RANKL is required for immuno-inflammatory signals to orchestrate 
bone loss (Lam et al., 2000).  
 
RANKL exists in both membrane-bound form and as a soluble form in circulation. In the 
circulation, it also exists in a bound form, complexed with OPG. OPG itself circulates in 
different forms, as a monomer, a dimer, and as a RANKL/OPG conjugate (Rogers et al., 
2005). Therefore, calculation of the ratio of RANKL to OPG was a relevant marker which 
was found to be increased in both PD and RA groups as compared to healthy subjects. Based 
on the fact that high RANKL/OPG ratio influences osteoclast activity, comparable levels of 
this ratio between RA and PD groups indicate an overall systemic bone resorptive status.  
Soluble TNF receptors has been suggested as negative modulators of TNF activity, therefore 
under normal conditions, TNF receptor concentrations exceed those of TNF. TNFR1 and 
TNFR2 both inhibit TNF-α, although binding to TNFR1 (177-fold) as compared to that of 
TNFR2 occurs with more ardency (Terlizzese et al., 1996).  In this study, an inverse 
correlation was found between TNFR1 levels and both MBL and deep pockets (≥5mm) in the 
PD group. Previous experimental studies have highlighted the antagonizing effects of soluble 
receptors on TNF-α, thereby preventing TNF-mediated bone loss (Assuma et al., 1998).  
Deep periodontal pockets form as a result of periodontal tissue attachment loss which is 
mediated by strong pro-inflammatory cytokines such as TNF-α. In the absence of 
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physiological TNF inhibitors, TNF mediated tissue loss will persist (Delima et al., 2001). 
TNFR1 concentrations tend to be higher in the sera of RA patients (Cope et al., 1992).  Our 
findings also showed TNFR1 levels to be the highest in the RA with PD group. This may 
reflect the accumulation of TNFR1 shedding in inflamed periodontal tissues as well as 
synovial inflammation. TNF receptors have also been detected in GCF where PPD values 
were higher (Ikezawa et al., 2005). The level of TNFR2 were also the highest in the RA with 
PD group, decreasing across remaining groups. High TNFR2 levels in RA patients have been 
reported before (Barton et al., 2001). 
 
The differences in shedding mechanisms may explain the difference between TNFR1 and 
TNFR2 levels. TNFR1 is pro-apoptotic while TNFR2 signals cell survival (Faustman et al., 
2013). In autoimmune diseases, defects such as polymorphisms in the TNFR2 gene may up 
regulate its expression and shedding. This excessive shedding may be a mechanism for 
indirectly antagonizing TNFR1 which would consequently reduce TNF-α activity. Since 
previous studies have also shown levels of soluble TNFR2 exceeding those of TNFR1, this 
emphasizes the dominancy of TNFR2 in order to be able to down-regulate TNF-α responses 
(Carpenter et al., 1995).  
 
Determination of the level of co-regulation between the osteoclastogenic markers showed 
that TNFR1 and TNFR2 were significantly associated in all four groups, with the strongest 
coefficient in the PD group. TNFR1 correlated with all three markers (OPN, RANKL and 
TNFR2) in both RA groups. For the PD group, TNFR1 was found to correlate with OPN but 
not with RANKL. TNFα is an inhibitor of bone formation as it stimulates, via TNFR1, the 
production of Dickkopf-1 (DKK-1). DKK-1 is a secreted glycoprotein which inhibits a cell 
signaling pathway that controls tissue regeneration in adult bone marrow (Diarra et al., 2007). 
Apoptosis of periodontal ligament cells in PD via TNFR1 stimulation is another mechanism 
which reduces bone formation as this diminishes the number of osteoblast precursor cells 
(Graves et al., 2011).  
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STUDY IV 
In study IV, we examined periodontal disease severity using a new index ΣPPD Total and 
ΣPPD disease and examined the glycemic regulatory status by measuring HbA1c levels in 
subjects with and without RA. As knowledge regarding the etiopathogenesis of PD increases 
with research, so does the need to discover and employ improved methods of disease 
measurement.  
 
The selection of a disease measuring index should be composed of assessments which are 
governed by parameters sensitive to change. Periodontal pocket formation is one such 
parameter considered in terms of tissue responsiveness to inflammation. Inflammatory 
changes cause the fibroblasts and collagen fibers around the epithelial ridges to be lost only to 
be replaced by immuno-inflammatory cells. Epithelial attachment at the base of the pocket 
extends not only apically but horizontally as well (Bosshardt, 2017). The response observed 
upon reduction of the inflammation is formation of a new epithelial attachment, thus reducing 
probing depth measurement (Saminsky et al., 2015). The rationale behind the use of 
continuous variables that are dichotomized in most periodontal research is that periodontal 
pocketing and bone loss do not occur uniformly throughout the entire dentition, so dichotomy 
helps overcome this uneven characteristic (Dye et al., 2002). 
 
The main disadvantage of dichotomising is loss of information hence reducing the statistical 
power to detect a relation between the variable and outcome. Secondly and naturally, with 
loss of data, there is underestimation of variability between groups (Cohen, 1983). We, 
therefore, developed a continuous disease measurement index with three parts unified by the 
basic principle of recording a direct representation of the extent of PPD with no loss of data. 
The first part of the index, ΣPPD Total, is simply an arithmetic sum of all measurable sites 
per subject. The second part, ΣPPD Disease, is a sub-aggregate which provides the total sum 
of diseased sites. The final part is an adjustment of ΣPPD Total to the number of teeth. 
Therefore, tooth and site-specific information is included ensuring no loss of data. We 
performed a correlation analysis to determine the potential of the ΣPPD Total index validity. 
Our results showed a high degree of correlation between all three of its components and 
number of deep pockets. The inverse correlation between tooth adjusted ratio and PPD 
disease was indicative of disease severity as higher ΣPPD disease correlated with lesser 
number of teeth and vice versa. Furthermore, our results revealed that the tooth adjusted 
ΣPPD total was able to gauge disease severity adequately as it associated significantly with 
parameters of PD severity.  
 
The disease activity measurement for RA employed the DAS28 index which is a composite 
continuous index comprising of several component variables, including swollen and tender 
joint count, with a high contribution of acute-phase reactant (CRP or ESR) levels. 
Radiographic progression in RA is known to be associated with swollen joint count and 
acute-phase reactants. DAS28, based on ESR, correlated with IgM-RF values in both RA 
with and without PD subjects which has also been reported by another study (Ursum et al., 
2010). Auto-antibody RF is one of the most powerful predictors of joint damage in early RA 
and RF positive RA patients demonstrate an increase in the DAS28 score in relation to an 
increase in radiologic damage (Welsing et al., 2004). Interestingly, this association did not 
seem to be affected by the status of periodontal health amongst RA subjects. Perhaps due to 
its composite nature and complex pathogenesis of RA, little or no association has been 
reported between DAS28 and periodontal parameters. However, we found that the number of 
 43 
 
shallow pockets was the only periodontal parameter to be significantly and inversely 
correlated with DAS28 in RA with PD subjects.  This may partly be explained by the fact that 
serum inflammatory cytokines and chemokines were also found to correlate inversely with 
shallow pockets in RA subjects with PD, aligning the serological representation with clinical 
activity (Panezai et al., 2017). 
 
When it comes to a glycemic disorders or metabolic disease such as diabetes mellitus, 
laboratory measures reflect severity. The persistence of inflammatory cytokines can play a 
crucial role in the development of insulin resistance both in RA and PD patients, placing 
them at risk for T2D (Solomon et al., 2010, Gaurav, 2012). In order to assess and compare 
the extent of glycemic disorder between RA and PD subjects, HbA1c levels were 
investigated. Our results showed a direct association between HbA1c levels and PD severity 
in terms of PPD index and bone loss. These findings are similar to that of a recent study 
where HbA1c levels were found to be higher amongst subjects with severe periodontal 
disease (Teeuw et al., 2017). 
 
Serum levels of HbA1c showed that glycemic disorder was the greatest in PD group, 
although statistically, there was no difference on comparison with the RA without PD group. 
We also found in study III their osteoimmunological inflammatory profile to be comparable 
(Panezai et al., 2018). Although all three disease groups showed higher HbA1c levels as 
compared to healthy controls, the lower levels in RA subjects in comparison to PD maybe 
explained by the use of disease modifying anti-rheumatic drugs (DMARDs) in this group. 
Certain DMARDs such as methotrexate and hydroxychloroquine have been shown to 
improve insulin sensitivity which reduces HbA1c levels in RA subjects (Rekedal et al., 
2010). 
 
 
CONCLUSIONS 
This thesis shows that periodontal disease is mirrored by a range of systemic immune 
markers, particularly those involved in inflammation. Furthermore, peripheral 
osteoclastogenesis is a feature of PD, comparable to RA.  In addition, it also signifies the 
peripheral involvement of host immune system and its effects on the glycemic regulation in 
both PD and RA groups.  The use of a simple summation of several variables without 
dichotomising provides the basis for sensitive approach towards PD measurement. The thesis 
also shows evidence that LRP1 controls motility, adhesion and activation in T cells.  
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FUTURE PERSPECTIVES IN LIGHT OF NOVEL FINDINGS 
 
Periodontal conditions are diagnosed clinically and radiographically however their severity is 
not limited to the confines of the oral cavity. PD is well reflected by host derived systemic 
inflammatory cytokines, chemokines, enzymes and growth factors.  
 
Peripheral Osteoclastogenesis and PD 
This thesis showed that serum levels of osteoclastogenic marker RANKL and bone resorptive 
status (RANKL/OPG ratio) was comparable between PD and RA disease groups. In light of 
this, further research will focus on gauging PD osteolytic effects in comparison to subjects 
with cardiovascular diseases (CVD) and T2D.  
 
Associated biomarkers and PD 
Due to high inter individual variability, correlation statistical analyses was chosen over inter 
group comparison when measuring an extensive array of biomarkers (study II) which 
revealed a clear consistency for novel markers FGF-19, ST1A1 and NT3 directly associated 
with PD parameters (BOP, PPD≥5mm and MBL). Further research will be planned 
capitalizing on these findings and studying these markers in subjects with PD and attendant 
comorbidities such as CVD and T2D. 
 
PPD Total and PPD Disease index 
Further research regarding the use of a novel index, ΣPPD Total and ΣPPD Disease are 
required to validate its use and establish its sensitivity and specificity in comparison to other 
indices. 
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POPULAR SCIENCE 
 
Periodontal disease (PD) affects the supporting tissues around the tooth including gum and 
bone. It is the leading cause of tooth loss in adults. The bacteria in oral plaque has been 
attributed as a trigger for periodontal disease, however there is enough supporting evidence to 
show that it is the immune response of the host that is responsible for the severity of the 
disease. 
 
This thesis focused on elucidating the involvement of the host response in subjects who were 
suffering from PD. They were compared with subjects suffering from rheumatoid arthritis 
(RA), an autoimmune disease which involves a strong systemic immune response in a self-
directed attack against synovial joints. With this comparison, it was possible to gauge the 
extent of the immune response involvement in combating PD as an inflammatory disease. 
 
In study II , we measured the levels of 92 protein markers, most of which are known to play a 
role in inflammation, and performed analyses which would allow us to determine whether 
these markers were associated with periodontal conditions or not. In study III, we measured 
another set of markers which are specific for bone resorption. Again, we performed analyses 
to assess any association between PD severity and markers of bone resorption. In study IV, 
we developed a new method of measuring PD clinically and tried to elucidate any correlation 
with glycated hemoglobin blood levels. 
 
Our results showed that PD inflammation is indeed well reflected by markers of 
inflammation measurable in the blood. Most importantly, the levels for markers of bone 
resorption were similar between RA and PD groups. This is an important finding which 
shows the extent of inflammation imparted by poor periodontal health.  
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